{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How should levomilnacipran dosing be adjusted for an individual with the HTR2A rs7997012 A/A genotype?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"levomilnacipran\", \"Gene Name\": \"HTR2A\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf\", \"Content to Search\": \"Dosing or therapeutic recommendations for levomilnacipran based on HTR2A rs7997012 genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended fluvastatin dose for an individual with ABCG2 decreased function?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"fluvastatin\", \"Gene Name\": \"ABCG2\", \"CPIC Guideline Name\": \"The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf\", \"Content to Search\": \"Dose adjustment protocol for fluvastatin in individuals with ABCG2 decreased function.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of HMGCR in the mechanism of action of atorvastatin?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"atorvastatin\", \"Gene Name\": \"HMGCR\", \"CPIC Guideline Name\": \"The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf\", \"Content to Search\": \"Description of HMGCR as the pharmacological target of atorvastatin.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the role of the CYP2C19 enzyme in the pharmacokinetics of sertraline?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"sertraline\", \"Gene Name\": \"CYP2C19\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf\", \"Content to Search\": \"Description of CYP2C19's role as a primary metabolic pathway for sertraline.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How do CYP2R1 genotypes correlate with vitamin D bioactivation phenotypes?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of headache with ondansetron in individuals with reduced CYP1A2 function?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of the OPRM1 gene product in the context of tramadol therapy?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"tramadol\", \"Gene Name\": \"OPRM1\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf\", \"Content to Search\": \"Explanation of OPRM1's role as the mu-opioid receptor, the primary target for tramadol's active metabolite, O-desmethyltramadol.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "Are there specific fluorouracil dosing guidelines for patients with renal impairment and DPYD deficiency?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"fluorouracil\", \"Gene Name\": \"DPYD\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Dihydropyrimidine Dehydrogenase Genotype and Fluoropyrimidine Dosing: 2017 Update (October 2017).pdf\", \"Content to Search\": \"Dosing adjustments for fluorouracil in patients with both renal impairment and DPYD deficiency\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of the CYP3A4 enzyme in the metabolism of the RET/VEGFR/EGFR inhibitor vandetanib?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How do COMT genotypes correlate with paroxetine treatment outcomes in major depressive disorder?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of myopathy with pitavastatin in individuals with low-activity UGT1A3 variants?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the dosing recommendation for ibuprofen in pediatric patients with heterozygous TPMT variants?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How should tropisetron dosing be modified for a CYP2D6 poor metabolizer?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"tropisetron\", \"Gene Name\": \"CYP2D6\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 Genotype and Use of Ondansetron and Tropisetron (December 2016).pdf\", \"Content to Search\": \"Dose modification protocol for tropisetron in CYP2D6 poor metabolizers\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended rosuvastatin dose for an individual with ABCG2 decreased function?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"rosuvastatin\", \"Gene Name\": \"ABCG2\", \"CPIC Guideline Name\": \"The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf\", \"Content to Search\": \"Dose adjustment protocol for rosuvastatin in individuals with ABCG2 decreased function.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How do CYP3A4 genotypes map to palbociclib clearance and toxicity phenotypes?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What diplotypes define a CYP2D6 intermediate metabolizer?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"fluvoxamine\", \"Gene Name\": \"CYP2D6\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf\", \"Content to Search\": \"Diplotype definitions and activity scores for the CYP2D6 intermediate metabolizer phenotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How should alprazolam dosing be adjusted for a patient who is a CYP3A4 poor metabolizer?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the dosing recommendation for citalopram in adolescents with the SLC6A4 S/S genotype?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"citalopram\", \"Gene Name\": \"SLC6A4\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf\", \"Content to Search\": \"Dosing guidelines for citalopram in adolescent patients, adjusted for SLC6A4 genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How does the CES1 genotype correspond to the hydrolysis of clopidogrel's prodrug to its inactive metabolite?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the expected plasma concentrations of ondansetron in a CYP2D6 poor metabolizer compared to a normal metabolizer?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"ondansetron\", \"Gene Name\": \"CYP2D6\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 Genotype and Use of Ondansetron and Tropisetron (December 2016).pdf\", \"Content to Search\": \"Plasma concentration data or pharmacokinetic parameters for ondansetron in CYP2D6 poor metabolizers\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of the CYP3A4 enzyme in the metabolism of the FGFR inhibitor pemigatinib?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the suggested plasma S-warfarin concentrations for a CYP1A2 poor metabolizer?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the risk of non-response for an individual with the HTR2A rs6313 G/G genotype taking milnacipran?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"milnacipran\", \"Gene Name\": \"HTR2A\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf\", \"Content to Search\": \"Quantified risk or odds ratio for treatment non-response in milnacipran users with the HTR2A rs6313 G/G genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the suggested therapeutic response metric for ipilimumab in melanoma based on a patient's CTLA-4 genotype?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the dosing recommendation for naltrexone in pediatric patients with a COMT high-activity genotype?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"naltrexone\", \"Gene Name\": \"COMT\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf\", \"Content to Search\": \"Pediatric dosing guidelines for naltrexone adjusted for COMT high-activity genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the suggested therapeutic range for the sum of amitriptyline and nortriptyline concentrations, and how is it affected by CYP2D6 status?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"amitriptyline\", \"Gene Name\": \"CYP2D6\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC®) for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants: 2016 Update (December 2016).pdf\", \"Content to Search\": \"Therapeutic drug monitoring range for amitriptyline plus nortriptyline and its relation to CYP2D6 phenotype\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of dizziness and liver enzyme elevation with larotrectinib in patients with reduced CYP3A4 function?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended pravastatin dose for a CYP2C9 poor metabolizer?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"pravastatin\", \"Gene Name\": \"CYP2C9\", \"CPIC Guideline Name\": \"The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf\", \"Content to Search\": \"Dose adjustment protocol for pravastatin in CYP2C9 poor metabolizers.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the quantified risk of reduced blood pressure response for an individual with the ADRB1 Arg389Arg genotype when taking nadolol?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"nadolol\", \"Gene Name\": \"ADRB1\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Risk multipliers or clinical data on the efficacy of nadolol in patients with the ADRB1 Arg389Arg genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What G6PD genotypes are classified as deficient (e.g., Class I, II, or III variants)?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"mafenide\", \"Gene Name\": \"G6PD\", \"CPIC Guideline Name\": \"Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf\", \"Content to Search\": \"Definitions of G6PD genotypes and their classification into different functional/phenotypic classes of deficiency.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How should topotecan dosing be adjusted for a patient with a low-function ABCG2 genotype?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of neurotoxicity with ivermectin in individuals with ABCB1 variants that compromise the blood-brain barrier?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the dosing recommendation for daptomycin in patients on statin therapy with a SLCO1B1 low-function genotype?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the dosing recommendation for esmolol in patients with heart failure and an ADRA2C polymorphism associated with altered response?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"esmolol\", \"Gene Name\": \"ADRA2C\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Dosing guidelines for esmolol in heart failure patients, adjusted for ADRA2C genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the expected changes in heart rate response in a patient with the ADRB1 Ser49Gly polymorphism taking pindolol?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"pindolol\", \"Gene Name\": \"ADRB1\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Pharmacodynamic data for pindolol stratified by ADRB1 Ser49Gly genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of SAMS for an individual with ABCG2 decreased function taking pitavastatin?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"pitavastatin\", \"Gene Name\": \"ABCG2\", \"CPIC Guideline Name\": \"The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf\", \"Content to Search\": \"Quantified risk or odds ratio for SAMS in individuals with ABCG2 decreased function taking pitavastatin.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What SLC6A4 variants (e.g., 5-HTTLPR) are associated with altered escitalopram response?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"escitalopram\", \"Gene Name\": \"SLC6A4\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf\", \"Content to Search\": \"List and description of SLC6A4 variants and their corresponding impact on escitalopram response.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the dosing recommendation for pravastatin in pediatric patients with an HMGCR variant associated with reduced statin response?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"pravastatin\", \"Gene Name\": \"HMGCR\", \"CPIC Guideline Name\": \"The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf\", \"Content to Search\": \"Pediatric dosing adjustments for pravastatin based on HMGCR genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How do EPOR genotypes correlate with erythropoietin resistance phenotypes?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How do ABCB1 genotypes map to ondansetron anti-emetic response phenotypes?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What G6PD genotypes are classified as deficient (e.g., Class I, II, or III variants)?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"ofloxacin\", \"Gene Name\": \"G6PD\", \"CPIC Guideline Name\": \"Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf\", \"Content to Search\": \"Definitions of G6PD genotypes and their classification into different functional/phenotypic classes of deficiency.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended initial dose of diclofenac for a patient with a CYP2C9 poor metabolizer phenotype?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"diclofenac\", \"Gene Name\": \"CYP2C9\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf\", \"Content to Search\": \"Dose adjustment protocol for diclofenac in CYP2C9 poor metabolizers.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How should ifosfamide dosing be adjusted for a patient who is a CYP3A4 poor metabolizer?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the role, if any, of the CYP2C19 enzyme in the metabolism of desipramine?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"desipramine\", \"Gene Name\": \"CYP2C19\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC®) for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants: 2016 Update (December 2016).pdf\", \"Content to Search\": \"Function of CYP2C19 enzyme in the metabolic pathway of desipramine\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the risk of inadequate analgesia for individuals with the OPRM1 A118G variant when taking morphine?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"morphine\", \"Gene Name\": \"OPRM1\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf\", \"Content to Search\": \"Quantified risk or clinical evidence for reduced analgesic efficacy of morphine in patients with the OPRM1 A118G variant.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What HMGCR variants are associated with altered statin response?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"pravastatin\", \"Gene Name\": \"HMGCR\", \"CPIC Guideline Name\": \"The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf\", \"Content to Search\": \"Definitions of HMGCR variants or genotypes associated with altered statin efficacy.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of the CYP2D6 enzyme in the metabolism of nebivolol?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"nebivolol\", \"Gene Name\": \"CYP2D6\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Description of CYP2D6's role in nebivolol metabolism.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How do CYP3A4 genotypes map to saxagliptin bioactivation and clearance phenotypes?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "Is a dose adjustment for meloxicam recommended based on CYP2C8 genotype?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"meloxicam\", \"Gene Name\": \"CYP2C8\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf\", \"Content to Search\": \"Dose adjustment protocol for meloxicam based on CYP2C8 genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the expected LDL-C reduction levels in an individual with an HMGCR variant associated with reduced statin response taking pitavastatin?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"pitavastatin\", \"Gene Name\": \"HMGCR\", \"CPIC Guideline Name\": \"The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf\", \"Content to Search\": \"Pharmacodynamic data (LDL-C reduction) for pitavastatin based on HMGCR genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "Which ABCB1 genotypes are associated with altered fentanyl dose requirements for adequate analgesia?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended dose of posaconazole for a patient with a UGT1A4*3 allele?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "Is there an increased risk of adverse events with aspirin in patients with reduced-function CYP2C8 alleles?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"aspirin\", \"Gene Name\": \"CYP2C8\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf\", \"Content to Search\": \"Quantified risk data for adverse events in patients with reduced-function CYP2C8 alleles using aspirin.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the role of the RYR1 gene in the mechanism of methoxyflurane-triggered malignant hyperthermia?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"methoxyflurane\", \"Gene Name\": \"RYR1\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for the use of potent volatile anesthetic agents and succinylcholine in the context of RYR1 or CACNA1S genotypes.pdf\", \"Content to Search\": \"Explanation of the RYR1 gene function and its role in the pathophysiology of methoxyflurane-induced malignant hyperthermia.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended citalopram dose for a CYP2C19 ultrarapid metabolizer?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"citalopram\", \"Gene Name\": \"CYP2C19\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf\", \"Content to Search\": \"Dose adjustment protocol or alternative medication recommendation for citalopram in CYP2C19 ultrarapid metabolizers.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "Are there specific recommendations for aceclofenac use in elderly patients who are also CYP2C9 poor metabolizers?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"aceclofenac\", \"Gene Name\": \"CYP2C9\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf\", \"Content to Search\": \"Dosing guidance for aceclofenac in elderly CYP2C9 poor metabolizers.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended dose of mitomycin C for a patient with a specific variant in the NQO1 gene?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of the hERG potassium channel (encoded by KCNH2) and how is it blocked by sotalol?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How do SULT1A1 genotypes map to tamoxifen sulfation phenotypes?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the risk of SAMS for an individual with an HMGCR variant associated with reduced statin response when taking lovastatin?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"lovastatin\", \"Gene Name\": \"HMGCR\", \"CPIC Guideline Name\": \"The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf\", \"Content to Search\": \"Quantified risk data for SAMS in individuals with HMGCR variants taking lovastatin.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How should the initial warfarin dose be adjusted for a patient with a CYP2C9 *3/*3 genotype (poor metabolizer)?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"warfarin\", \"Gene Name\": \"CYP2C9\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for Pharmacogenetics-guided Warfarin Dosing: 2016 Update.pdf\", \"Content to Search\": \"Dose adjustment protocol or dosing algorithm for warfarin in CYP2C9 poor metabolizers\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How do VEGF-A genotypes correlate with bevacizumab efficacy and toxicity phenotypes?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the dosing recommendation for vilazodone in a pediatric patient with a CYP2D6 poor metabolizer phenotype?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"vilazodone\", \"Gene Name\": \"CYP2D6\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf\", \"Content to Search\": \"Pediatric dosing adjustments for vilazodone in CYP2D6 poor metabolizers.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the target plasma concentrations of 4-hydroxycyclophosphamide in a patient with a CYP2B6 intermediate metabolizer phenotype?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the target plasma concentrations for brigatinib in a patient with a CYP2C8 intermediate metabolizer phenotype?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What diplotypes define a CYP2D6 poor metabolizer?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"acebutolol\", \"Gene Name\": \"CYP2D6\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Diplotype definitions and activity scores for the CYP2D6 poor metabolizer phenotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the risk of severe hematologic toxicity for a NUDT15 poor metabolizer taking a standard dose of azathioprine?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"azathioprine\", \"Gene Name\": \"NUDT15\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium Guidelines for thiopurine dosing based on TPMT and NUDT15 genotypes: 2018 Update (November 2018).pdf\", \"Content to Search\": \"Quantified risk or incidence rate of severe myelosuppression in NUDT15 poor metabolizers using azathioprine\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the dosing recommendation for transdermal fentanyl in cancer patients with known ABCB1 variants?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of severe hematologic toxicity with pemetrexed in individuals with the MTHFR 677TT genotype?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the target plasma concentrations of acetaminophen glucuronide in a patient with a specific UGT1A6 diplotype?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended dose of lamotrigine for a patient with a UGT1A4*3 allele?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of the UGT1A4 and CYP1A2 enzymes in the detoxification of asenapine?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the suggested therapeutic range for plasma vilazodone concentrations in a CYP2C19 intermediate metabolizer?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"vilazodone\", \"Gene Name\": \"CYP2C19\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf\", \"Content to Search\": \"Plasma concentration ranges for vilazodone in CYP2C19 intermediate metabolizers.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended dose of finasteride for a patient with a SRD5A2 V89L polymorphism?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of the IL-5 receptor alpha chain (IL5RA) on eosinophils, the target of benralizumab?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How should sonidegib dosing be adjusted for a patient who is a CYP3A4 poor metabolizer?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What diplotypes define a CYP2D6 ultrarapid metabolizer?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"hydromorphone\", \"Gene Name\": \"CYP2D6\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf\", \"Content to Search\": \"Diplotype definitions and activity scores for the CYP2D6 ultrarapid metabolizer phenotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How should sufentanil dosing be adjusted for a CYP2D6 poor metabolizer?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"sufentanil\", \"Gene Name\": \"CYP2D6\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf\", \"Content to Search\": \"Dose adjustment protocol for sufentanil in CYP2D6 poor metabolizers.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What diplotypes define a CYP2D6 ultrarapid metabolizer?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"betaxolol\", \"Gene Name\": \"CYP2D6\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Diplotype definitions and activity scores for the CYP2D6 ultrarapid metabolizer phenotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of SAMS for a CYP3A5 normal metabolizer (expresser) taking fluvastatin?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"fluvastatin\", \"Gene Name\": \"CYP3A5\", \"CPIC Guideline Name\": \"The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf\", \"Content to Search\": \"Quantified risk data for SAMS in CYP3A5 normal metabolizers using fluvastatin.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the expected pharmacodynamic effects (e.g., heart rate reduction) in a patient with the ADRA2C Ins/Del polymorphism taking propranolol?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"propranolol\", \"Gene Name\": \"ADRA2C\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Pharmacodynamic data for propranolol stratified by ADRA2C genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the risk of inadequate analgesia for individuals with the OPRM1 A118G variant when taking levomethadone?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"levomethadone\", \"Gene Name\": \"OPRM1\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf\", \"Content to Search\": \"Quantified risk or clinical evidence for reduced analgesic efficacy of levomethadone in patients with the OPRM1 A118G variant.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How do UGT1A9 genotypes map to regorafenib clearance and toxicity phenotypes?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the quantified risk of acute hemolytic anemia for a G6PD deficient individual taking chloramphenicol?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"chloramphenicol\", \"Gene Name\": \"G6PD\", \"CPIC Guideline Name\": \"Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf\", \"Content to Search\": \"Incidence rates or risk multipliers for acute hemolytic anemia with chloramphenicol use in G6PD deficient patients.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the suggested therapeutic range for plasma fexofenadine concentrations in a patient with a specific SLCO1B1 diplotype?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of infusion-related reactions with ocrelizumab in individuals with specific FCGR3A variants?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the quantified risk of akathisia for lurasidone users with decreased CYP3A4 activity?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the primary metabolic pathway for nifedipine involving the CYP3A4 enzyme?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the role of CYP3A4 and CYP1A2 in the metabolic clearance of ziprasidone?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What diplotypes define a CYP2B6 normal metabolizer?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"desvenlafaxine\", \"Gene Name\": \"CYP2B6\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf\", \"Content to Search\": \"Diplotype definitions and activity scores for the CYP2B6 normal metabolizer phenotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the target blood pressure reduction for a losartan-treated patient based on their AGTR1 genotype?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How should pemetrexed dosing be adjusted for a patient with a MTHFR C677T polymorphism?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How should hydromorphone dosing be adjusted for an individual with an OPRM1 variant associated with decreased receptor function (e.g., A118G)?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"hydromorphone\", \"Gene Name\": \"OPRM1\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf\", \"Content to Search\": \"Dose adjustment protocol for hydromorphone based on OPRM1 variants affecting receptor function.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What G6PD genotypes are classified as deficient (e.g., Class I, II, or III variants)?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"hydroxychloroquine\", \"Gene Name\": \"G6PD\", \"CPIC Guideline Name\": \"Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf\", \"Content to Search\": \"Definitions of G6PD genotypes and their classification into different functional/phenotypic classes of deficiency.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How should lisdexamfetamine dosing be adjusted for a patient with a specific variant in a red blood cell enzyme responsible for its conversion?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the dosing recommendation for carvedilol in patients with heart failure and an ADRA2C polymorphism associated with altered response?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"carvedilol\", \"Gene Name\": \"ADRA2C\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Dosing guidelines for carvedilol in heart failure patients, adjusted for ADRA2C genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How should torsemide dosing be adjusted for a patient who is a CYP2C9 poor metabolizer?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the target plasma trough concentrations for dabigatran in a patient with a specific ABCB1 haplotype?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the quantified risk of adverse outcomes in heart failure for an individual with the GRK5 Leu41 variant when taking nebivolol?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"nebivolol\", \"Gene Name\": \"GRK5\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Risk multipliers or clinical data on heart failure outcomes with nebivolol in patients with the GRK5 Leu41 variant.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the expected plasma simvastatin concentrations in a CYP3A4 intermediate metabolizer?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"simvastatin\", \"Gene Name\": \"CYP3A4\", \"CPIC Guideline Name\": \"The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf\", \"Content to Search\": \"Plasma concentration ranges or AUC data for simvastatin in CYP3A4 intermediate metabolizers.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "Which RYR1 genotypes are associated with Malignant Hyperthermia Susceptibility?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"isoflurane\", \"Gene Name\": \"RYR1\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for the use of potent volatile anesthetic agents and succinylcholine in the context of RYR1 or CACNA1S genotypes.pdf\", \"Content to Search\": \"Diplotype or allele definitions for RYR1 that correspond to the Malignant Hyperthermia Susceptible phenotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the suggested therapeutic range for plasma buprenorphine concentrations in a patient with an OPRM1 variant leading to increased receptor expression?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"buprenorphine\", \"Gene Name\": \"OPRM1\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf\", \"Content to Search\": \"Therapeutic drug monitoring values for buprenorphine stratified by OPRM1 genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the target plasma concentrations for metformin in a patient with a high-function MATE1 genotype?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended dose of haloperidol for a patient who is a CYP2D6 poor metabolizer?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the expected pharmacodynamic effects on cardiac function in a patient with the GRK5 Gln41Gln genotype taking sotalol?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"sotalol\", \"Gene Name\": \"GRK5\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Pharmacodynamic data for sotalol stratified by GRK5 genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How should quinine dosing be adjusted for a patient who is a CYP3A4 poor metabolizer?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the dosing recommendation for betaxolol in patients with heart failure and a GRK5 polymorphism associated with altered response?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"betaxolol\", \"Gene Name\": \"GRK5\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Dosing guidelines for betaxolol in heart failure patients, adjusted for GRK5 genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of bradycardia with donepezil in CYP2D6 poor metabolizers?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the mechanism by which tegafur is converted to fluorouracil and subsequently metabolized by DPYD?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"tegafur\", \"Gene Name\": \"DPYD\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Dihydropyrimidine Dehydrogenase Genotype and Fluoropyrimidine Dosing: 2017 Update (October 2017).pdf\", \"Content to Search\": \"Metabolic pathway of tegafur to 5-fluorouracil and its subsequent catabolism by DPYD\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the expected clinical response to fluoxetine in a patient with the SLC6A4 L/S genotype?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"fluoxetine\", \"Gene Name\": \"SLC6A4\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf\", \"Content to Search\": \"Pharmacodynamic data, such as remission rates, for fluoxetine stratified by SLC6A4 5-HTTLPR genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How does MGMT promoter methylation status correlate with dacarbazine resistance phenotypes?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How does CYP2C19 polymorphism affect the first-pass metabolism of lansoprazole?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"lansoprazole\", \"Gene Name\": \"CYP2C19\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C19 and Proton Pump Inhibitor Dosing (August 2020).pdf\", \"Content to Search\": \"Description of CYP2C19's role in lansoprazole's mechanism and metabolism.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What diplotypes define a CYP2C19 normal metabolizer?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"venlafaxine\", \"Gene Name\": \"CYP2C19\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf\", \"Content to Search\": \"Diplotype definitions and activity scores for the CYP2C19 normal metabolizer phenotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the suggested therapeutic response metric for calcitriol in secondary hyperparathyroidism based on VDR genotype?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of SAMS for a CYP3A5 normal metabolizer (expresser) taking lovastatin?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"lovastatin\", \"Gene Name\": \"CYP3A5\", \"CPIC Guideline Name\": \"The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf\", \"Content to Search\": \"Quantified risk data for SAMS in CYP3A5 normal metabolizers using lovastatin.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of the UGT1A1 enzyme in the glucuronidation of atorvastatin metabolites?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended nadolol dose for an individual with the GRK5 Gln41Leu polymorphism?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"nadolol\", \"Gene Name\": \"GRK5\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Dose adjustment protocol for nadolol based on GRK5 Gln41Leu genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the suggested therapeutic range for plasma morphine concentrations in a codeine-treated patient who is a CYP3A4 rapid metabolizer?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the suggested therapeutic range for plasma sunitinib concentrations in a CYP3A4 rapid metabolizer?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of poor response to methylphenidate in individuals with high-activity CES1 variants?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of the CYP2D6 enzyme in the metabolism of remifentanil?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"remifentanil\", \"Gene Name\": \"CYP2D6\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf\", \"Content to Search\": \"Description of CYP2D6's role in remifentanil metabolism.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of Torsades de Pointes with quinidine in individuals who are CYP2D6 poor metabolizers?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the target plasma concentrations of ramelteon's active metabolite in a patient with a CYP1A2 rapid metabolizer phenotype?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended dose reduction for desipramine in a CYP2D6 poor metabolizer?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"desipramine\", \"Gene Name\": \"CYP2D6\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC®) for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants: 2016 Update (December 2016).pdf\", \"Content to Search\": \"Specific dose reduction percentage for desipramine in CYP2D6 poor metabolizers\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the quantified risk of ototoxicity when administering tobramycin to a patient with a pathogenic MT-RNR1 variant?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"tobramycin\", \"Gene Name\": \"MT-RNR1\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for MT-RNR1 and Aminoglycosides (May 2021).pdf\", \"Content to Search\": \"Incidence rates or risk multipliers for tobramycin-induced ototoxicity in MT-RNR1 variant carriers.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the contribution of CYP2C8 to the overall clearance of aspirin?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"aspirin\", \"Gene Name\": \"CYP2C8\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf\", \"Content to Search\": \"Description of CYP2C8's role in aspirin's metabolic pathway.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the suggested therapeutic range for plasma vortioxetine concentrations in a CYP2C19 intermediate metabolizer?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"vortioxetine\", \"Gene Name\": \"CYP2C19\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf\", \"Content to Search\": \"Plasma concentration ranges for vortioxetine in CYP2C19 intermediate metabolizers.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the risk of therapeutic failure for a CYP2D6 ultrarapid metabolizer on a standard dose of clomipramine?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"clomipramine\", \"Gene Name\": \"CYP2D6\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC®) for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants: 2016 Update (December 2016).pdf\", \"Content to Search\": \"Quantified risk of non-response or therapeutic failure in CYP2D6 ultrarapid metabolizers taking clomipramine\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the basic mechanism by which apolipoprotein E isoforms might influence warfarin metabolism or sensitivity?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the risk of treatment failure with standard omeprazole dosing for a CYP2C19 ultrarapid metabolizer?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"omeprazole\", \"Gene Name\": \"CYP2C19\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C19 and Proton Pump Inhibitor Dosing (August 2020).pdf\", \"Content to Search\": \"Quantified risk data for therapeutic failure in CYP2C19 ultrarapid metabolizers using omeprazole.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What diplotypes define a CYP2B6 intermediate metabolizer?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"efavirenz\", \"Gene Name\": \"CYP2B6\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2B6 and Efavirenz-containing Antiretroviral Therapy (April 2019).pdf\", \"Content to Search\": \"Diplotype definitions corresponding to the CYP2B6 intermediate metabolizer phenotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the role of the ATM gene in the cellular response to metformin?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "Are there specific trimipramine dosing recommendations for pregnant patients who are CYP2C19 poor metabolizers?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"trimipramine\", \"Gene Name\": \"CYP2C19\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC®) for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants: 2016 Update (December 2016).pdf\", \"Content to Search\": \"Dosing guidance for trimipramine during pregnancy for CYP2C19 poor metabolizers\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the primary metabolic pathway for olanzapine involving the CYP1A2 enzyme?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of elevated liver enzymes with caspofungin in individuals with the SLCO1B1 c.521T>C polymorphism?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended dosing for desflurane in a patient with a CACNA1S genotype conferring Malignant Hyperthermia Susceptibility?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"desflurane\", \"Gene Name\": \"CACNA1S\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for the use of potent volatile anesthetic agents and succinylcholine in the context of RYR1 or CACNA1S genotypes.pdf\", \"Content to Search\": \"Dosing protocol or avoidance recommendation for desflurane in patients with CACNA1S-Malignant Hyperthermia Susceptibility.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What genotypes of the HTR2A gene (e.g., rs6313) are associated with altered venlafaxine response?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"venlafaxine\", \"Gene Name\": \"HTR2A\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf\", \"Content to Search\": \"Definitions of HTR2A genotypes and their association with venlafaxine efficacy.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the dosing recommendation for atorvastatin in pediatric patients with a CYP3A4 poor metabolizer phenotype?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"atorvastatin\", \"Gene Name\": \"CYP3A4\", \"CPIC Guideline Name\": \"The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf\", \"Content to Search\": \"Pediatric dosing adjustments for atorvastatin in CYP3A4 poor metabolizers.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the expected hematological changes in a G6PD deficient individual exposed to rasburicase?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"rasburicase\", \"Gene Name\": \"G6PD\", \"CPIC Guideline Name\": \"Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf\", \"Content to Search\": \"Data on hematological parameters in G6PD deficient individuals after rasburicase administration.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the expected hematological changes in a G6PD deficient individual exposed to mesalazine?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"mesalazine\", \"Gene Name\": \"G6PD\", \"CPIC Guideline Name\": \"Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf\", \"Content to Search\": \"Data on hematological parameters in G6PD deficient individuals after mesalazine administration.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of hyperglycemia and hyperlipidemia with temsirolimus in individuals with reduced CYP3A4 function?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of the OPRM1 gene product in the context of buprenorphine therapy?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"buprenorphine\", \"Gene Name\": \"OPRM1\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf\", \"Content to Search\": \"Explanation of OPRM1's role as the mu-opioid receptor, a primary target for buprenorphine.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the dosing recommendation for pindolol in pediatric patients with hypertension and the ADRB1 Arg389Gly polymorphism?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"pindolol\", \"Gene Name\": \"ADRB1\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Pediatric dosing guidelines for pindolol adjusted for ADRB1 genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the relative risk of over-anticoagulation for a patient with a sensitive VKORC1 genotype when starting warfarin?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"warfarin\", \"Gene Name\": \"VKORC1\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for Pharmacogenetics-guided Warfarin Dosing: 2016 Update.pdf\", \"Content to Search\": \"Quantified risk data for supratherapeutic INR in patients with a sensitive VKORC1 genotype\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the role of the mu-opioid receptor (encoded by OPRM1) in the therapeutic mechanism of escitalopram?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the expected hematological changes in a G6PD deficient individual exposed to toluidine blue?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"toluidine blue\", \"Gene Name\": \"G6PD\", \"CPIC Guideline Name\": \"Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf\", \"Content to Search\": \"Data on hematological parameters in G6PD deficient individuals after toluidine blue administration.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of hepatotoxicity with azathioprine in individuals with a GSTT1-null genotype?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the expected plasma concentrations of levomilnacipran in a CYP2D6 ultrarapid metabolizer?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"levomilnacipran\", \"Gene Name\": \"CYP2D6\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf\", \"Content to Search\": \"Plasma concentration ranges or AUC data for levomilnacipran in CYP2D6 ultrarapid metabolizers.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How do SLC22A6 genotypes correlate with ganciclovir renal clearance and toxicity phenotypes?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the target plasma concentrations for modafinil acid in a patient with a CYP3A4 rapid metabolizer phenotype?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "Is sulfisoxazole contraindicated or should dosing be adjusted for a G6PD deficient individual?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"sulfisoxazole\", \"Gene Name\": \"G6PD\", \"CPIC Guideline Name\": \"Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf\", \"Content to Search\": \"Dosing protocol or contraindication for sulfisoxazole in G6PD deficient individuals.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the target plasma concentration for the sum of clomipramine and desmethylclomipramine, and how is it influenced by CYP2D6 phenotype?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"clomipramine\", \"Gene Name\": \"CYP2D6\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC®) for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants: 2016 Update (December 2016).pdf\", \"Content to Search\": \"Therapeutic drug monitoring range for clomipramine plus its metabolite and its relation to CYP2D6 status\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the quantified risk of adverse effects for a CYP2C19 ultrarapid metabolizer taking vortioxetine?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"vortioxetine\", \"Gene Name\": \"CYP2C19\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf\", \"Content to Search\": \"Quantified risk data for adverse effects in CYP2C19 ultrarapid metabolizers using vortioxetine.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the expected clinical response to duloxetine in a patient with the SLC6A4 L/S genotype?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"duloxetine\", \"Gene Name\": \"SLC6A4\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf\", \"Content to Search\": \"Pharmacodynamic data, such as remission rates, for duloxetine stratified by SLC6A4 5-HTTLPR genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended dose of aprepitant for a patient identified as a CYP3A4 ultrarapid metabolizer?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the target plasma concentrations for venetoclax during the dose ramp-up phase in a patient with a CYP3A4 rapid metabolizer phenotype?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the suggested C-peptide level target for an insulin-treated patient based on their KCNJ11 genotype?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the suggested therapeutic range for plasma tropisetron concentrations?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"tropisetron\", \"Gene Name\": \"CYP2D6\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 Genotype and Use of Ondansetron and Tropisetron (December 2016).pdf\", \"Content to Search\": \"Therapeutic range for plasma tropisetron concentrations\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the mechanism by which MT-RNR1 variants increase susceptibility to dibekacin-induced ototoxicity?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"dibekacin\", \"Gene Name\": \"MT-RNR1\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for MT-RNR1 and Aminoglycosides (May 2021).pdf\", \"Content to Search\": \"Functional explanation of how MT-RNR1 variants interact with dibekacin to cause cellular damage.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What ADRB1 genotypes are associated with enhanced beta-blocker response?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"carvedilol\", \"Gene Name\": \"ADRB1\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Definitions of ADRB1 genotypes (e.g., Arg389Arg) and their association with increased beta-blocker efficacy.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the dosing recommendation for alfentanil in pediatric patients with a COMT high-activity genotype?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"alfentanil\", \"Gene Name\": \"COMT\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf\", \"Content to Search\": \"Pediatric dosing guidelines for alfentanil adjusted for COMT high-activity genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the dosing recommendation for nadolol in pediatric patients with hypertension and the ADRB1 Arg389Gly polymorphism?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"nadolol\", \"Gene Name\": \"ADRB1\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Pediatric dosing guidelines for nadolol adjusted for ADRB1 genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the expected hematological changes in a G6PD deficient individual exposed to tafenoquine?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"tafenoquine\", \"Gene Name\": \"G6PD\", \"CPIC Guideline Name\": \"Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf\", \"Content to Search\": \"Data on hematological parameters in G6PD deficient individuals after tafenoquine administration.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of the Angiotensin II Receptor Type 1 (AGTR1), the target of losartan, and how do its variants alter drug binding?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of the CYP3A4 enzyme in the metabolism of the EGFR T790M inhibitor osimertinib?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the quantified risk of acute hemolytic anemia for a G6PD deficient individual taking vitamin K?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"vitamin k\", \"Gene Name\": \"G6PD\", \"CPIC Guideline Name\": \"Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf\", \"Content to Search\": \"Incidence rates or risk multipliers for acute hemolytic anemia with vitamin K use in G6PD deficient patients.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the dosing recommendation for chlorpropamide in an elderly patient with G6PD deficiency and renal impairment?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"chlorpropamide\", \"Gene Name\": \"G6PD\", \"CPIC Guideline Name\": \"Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf\", \"Content to Search\": \"Dosing guidelines for chlorpropamide in elderly G6PD deficient patients with comorbidities like renal impairment.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended dose of bortezomib for a patient with a specific variant in a proteasome subunit gene (e.g., PSMB5)?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How should bisoprolol dosing be adjusted for an individual with an ADRA2C polymorphism associated with altered response?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"bisoprolol\", \"Gene Name\": \"ADRA2C\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Dose adjustment protocol for bisoprolol based on ADRA2C genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of the CYP2D6 enzyme in the metabolism of sotalol?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"sotalol\", \"Gene Name\": \"CYP2D6\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Description of CYP2D6's role in sotalol metabolism.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How do Glutathione S-Transferase (GST) genotypes correlate with azathioprine toxicity phenotypes?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of phenytoin toxicity for a CYP2C9 intermediate metabolizer?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"phenytoin\", \"Gene Name\": \"CYP2C9\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP2C9 and HLA-B Genotype and Phenytoin Dosing (August 2020).pdf\", \"Content to Search\": \"Quantified risk data for phenytoin toxicity in CYP2C9 intermediate metabolizers\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended dose of dasatinib for a patient with the ABCG2 Q141K variant?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How should procainamide dosing be adjusted for a patient with a NAT2 slow acetylator genotype?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How should trimipramine dosing be adjusted for a CYP2C19 poor metabolizer?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"trimipramine\", \"Gene Name\": \"CYP2C19\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC®) for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants: 2016 Update (December 2016).pdf\", \"Content to Search\": \"Dose adjustment protocol for trimipramine in CYP2C19 poor metabolizers\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the plasma concentration thresholds for cisplatin-induced nephrotoxicity based on TPMT genotype?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How do ABCB1 haplotypes correspond to digoxin clearance phenotypes?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the dosing recommendation for furazolidone in a pediatric patient with G6PD deficiency?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"furazolidone\", \"Gene Name\": \"G6PD\", \"CPIC Guideline Name\": \"Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf\", \"Content to Search\": \"Pediatric-specific dosing guidelines for furazolidone in G6PD deficient children.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the clinical significance of the HLA-A*31:01 allele for oxcarbazepine therapy?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"oxcarbazepine\", \"Gene Name\": \"HLA-A\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for HLA Genotype and Use of Carbamazepine and Oxcarbazepine: 2017 Update (December 2017).pdf\", \"Content to Search\": \"Definition of clinical phenotype or implication of HLA-A*31:01 positivity for oxcarbazepine use\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the risk of hypercalciuria with calcitriol in individuals with gain-of-function VDR polymorphisms?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the risk of non-response for an individual with the SLC6A4 s/s genotype taking vilazodone?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"vilazodone\", \"Gene Name\": \"SLC6A4\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf\", \"Content to Search\": \"Quantified risk or odds ratio for treatment non-response in vilazodone users with the SLC6A4 s/s genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of adverse events in a CYP2D6 poor metabolizer taking doxepin?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"doxepin\", \"Gene Name\": \"CYP2D6\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC®) for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants: 2016 Update (December 2016).pdf\", \"Content to Search\": \"Quantified risk of adverse events in CYP2D6 poor metabolizers on doxepin\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the target level of acetylcholinesterase inhibition for a donepezil-treated patient based on their ACHE genotype?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of Catechol-O-methyltransferase (COMT) in the peripheral metabolism of levodopa?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the dosing recommendation for pravastatin in pediatric patients with SLCO1B1 low function?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"pravastatin\", \"Gene Name\": \"SLCO1B1\", \"CPIC Guideline Name\": \"The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf\", \"Content to Search\": \"Pediatric dosing guidelines for pravastatin adjusted for SLCO1B1 low function.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How do CYP3A4 genotypes map to glasdegib clearance phenotypes?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended dose of colchicine for a patient with a low-function ABCB1 genotype?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How does the PON1 genotype correspond to clopidogrel bioactivation phenotypes?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the target plasma concentrations for lapatinib in a patient with a CYP3A4 rapid metabolizer phenotype?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How do SLCO1B1 genotypes correlate with eltrombopag clearance and toxicity phenotypes?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of the ADRA2C gene product in the context of esmolol therapy?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"esmolol\", \"Gene Name\": \"ADRA2C\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Explanation of the role of the alpha-2C adrenergic receptor in cardiovascular regulation and its interaction with esmolol.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of diarrhea with aliskiren in individuals with the ABCB1 3435C>T polymorphism?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "Is there an increased risk of adverse events with meloxicam in patients with reduced-function CYP2C8 alleles?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"meloxicam\", \"Gene Name\": \"CYP2C8\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf\", \"Content to Search\": \"Quantified risk data for adverse events in patients with reduced-function CYP2C8 alleles using meloxicam.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How do GLP1R genotypes define response phenotypes to semaglutide therapy?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of pancreatitis with fenofibrate in individuals with specific UGT1A9 variants?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "Is the dosing of peginterferon alfa-2a modified based on the IFNL4-ΔG/TT genotype (rs368234815)?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"peginterferon alfa-2a\", \"Gene Name\": \"IFNL4\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for IFNL3 (IL28B) Genotype and PEG interferon-alpha-based Regimens (February 2014).pdf\", \"Content to Search\": \"Dose adjustment protocol for peginterferon alfa-2a based on IFNL4 genotype\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How should memantine dosing be adjusted for a patient with a low-function SLC22A2 genotype?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What ADRA2C polymorphisms are associated with altered beta-blocker response?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"metoprolol\", \"Gene Name\": \"ADRA2C\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Definitions of ADRA2C polymorphisms (e.g., Ins/Del) and their impact on beta-blocker therapy.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of life-threatening hyperkalemia with eplerenone in individuals with reduced CYP3A4 function?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the quantified risk of reduced blood pressure response for an individual with the ADRA2C Ins/Del polymorphism when taking metoprolol?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"metoprolol\", \"Gene Name\": \"ADRA2C\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Risk multipliers or clinical data on reduced efficacy of metoprolol in patients with the ADRA2C Ins/Del polymorphism.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How should metoprolol dosing be adjusted based on a patient's ADRB1 Ser49Gly polymorphism?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How should paroxetine dosing be adjusted for an individual with the SLC6A4 l/l genotype?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"paroxetine\", \"Gene Name\": \"SLC6A4\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf\", \"Content to Search\": \"Dose adjustment protocol for paroxetine based on SLC6A4 5-HTTLPR genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How do MPL genotypes correlate with romiplostim efficacy phenotypes?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the risk of inadequate analgesia for individuals with the OPRM1 A118G variant when taking remifentanil?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"remifentanil\", \"Gene Name\": \"OPRM1\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf\", \"Content to Search\": \"Quantified risk or clinical evidence for reduced analgesic efficacy of remifentanil in patients with the OPRM1 A118G variant.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of agranulocytosis with clozapine in patients with reduced CYP1A2 function, especially smokers?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How does the CYP2C8*3 allele affect the pharmacokinetics of ibuprofen?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"ibuprofen\", \"Gene Name\": \"CYP2C8\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf\", \"Content to Search\": \"Pharmacokinetic data on ibuprofen exposure related to the CYP2C8*3 allele.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of the SLCO1B1 transporter in the pharmacokinetics of lovastatin?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"lovastatin\", \"Gene Name\": \"SLCO1B1\", \"CPIC Guideline Name\": \"The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf\", \"Content to Search\": \"Description of SLCO1B1's role as a hepatic uptake transporter affecting lovastatin clearance.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How do UGT1A1 genotypes correlate with dolutegravir clearance phenotypes?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How should temozolomide dosing be adjusted for a patient with an unmethylated MGMT promoter in their tumor?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What diplotypes are classified as CYP2C19 intermediate metabolizers?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"voriconazole\", \"Gene Name\": \"CYP2C19\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C19 and Voriconazole Therapy (December 2016).pdf\", \"Content to Search\": \"Diplotype definitions for the CYP2C19 intermediate metabolizer phenotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How do UGT1A4 genotypes map to asenapine glucuronidation phenotypes?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the expected pharmacodynamic effects (e.g., change in blood pressure) in a patient with the ADRB2 Gln27Glu polymorphism taking bisoprolol?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"bisoprolol\", \"Gene Name\": \"ADRB2\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Pharmacodynamic data for bisoprolol stratified by ADRB2 genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the dosing recommendation for vortioxetine in a pediatric patient with a CYP2D6 poor metabolizer phenotype?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"vortioxetine\", \"Gene Name\": \"CYP2D6\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf\", \"Content to Search\": \"Pediatric dosing adjustments for vortioxetine in CYP2D6 poor metabolizers.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "Does the presence of the HLA-B*15:02 allele alter the pharmacokinetic profile of phenytoin derived from fosphenytoin?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"fosphenytoin\", \"Gene Name\": \"HLA-B\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP2C9 and HLA-B Genotype and Phenytoin Dosing (August 2020).pdf\", \"Content to Search\": \"Pharmacokinetic data (e.g., plasma concentration) of phenytoin based on HLA-B*15:02 status after fosphenytoin administration\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the risk of inadequate analgesia for individuals with the OPRM1 A118G variant when taking buprenorphine?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"buprenorphine\", \"Gene Name\": \"OPRM1\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf\", \"Content to Search\": \"Quantified risk or clinical evidence for reduced analgesic efficacy of buprenorphine in patients with the OPRM1 A118G variant.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How should methadone dosing be adjusted for a patient who is a CYP2B6 poor metabolizer?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How should itraconazole dosing be adjusted for a patient who is a CYP3A4 poor metabolizer?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the suggested therapeutic range for plasma d-amphetamine concentrations following lisdexamfetamine administration based on a patient's genotype?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of myopathy with rosuvastatin in individuals who are CYP2D6 poor metabolizers?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the target plasma concentrations for nirmatrelvir in a patient with a CYP3A4 rapid metabolizer phenotype?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the risk of treatment failure with cefuroxime in infections caused by bacteria with altered PBP genes?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What G6PD genotypes are classified as deficient (e.g., Class I, II, or III variants)?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"sulfadimidine\", \"Gene Name\": \"G6PD\", \"CPIC Guideline Name\": \"Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf\", \"Content to Search\": \"Definitions of G6PD genotypes and their classification into different functional/phenotypic classes of deficiency.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the target level of serum calcium reduction for a pamidronate-treated patient with hypercalcemia of malignancy, based on their FDPS genotype?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended sotalol dose for an individual with the ADRB1 Arg389Gly polymorphism (Gly/Gly genotype)?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"sotalol\", \"Gene Name\": \"ADRB1\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Dose adjustment protocol for sotalol based on ADRB1 Arg389Gly genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the quantified risk of reduced therapeutic response for an individual with the ADRA2C Ins/Del polymorphism taking bisoprolol?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"bisoprolol\", \"Gene Name\": \"ADRA2C\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Quantified risk data for reduced efficacy (e.g., blood pressure control) in individuals with the ADRA2C Ins/Del polymorphism taking bisoprolol.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the suggested level of proteasome inhibition for a bortezomib-treated patient based on their proteasome subunit genotype?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended dose of lapatinib for a patient who is a CYP3A4 poor metabolizer?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the quantified risk of malignant hyperthermia when administering isoflurane to a patient with a pathogenic RYR1 variant?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"isoflurane\", \"Gene Name\": \"RYR1\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for the use of potent volatile anesthetic agents and succinylcholine in the context of RYR1 or CACNA1S genotypes.pdf\", \"Content to Search\": \"Incidence rates or risk data for isoflurane-triggered malignant hyperthermia in patients with pathogenic RYR1 variants.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How do ABCB1 genotypes correlate with tamoxifen resistance phenotypes in breast cancer?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the expected plasma simvastatin concentrations in a CYP3A5 normal metabolizer (expresser)?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"simvastatin\", \"Gene Name\": \"CYP3A5\", \"CPIC Guideline Name\": \"The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf\", \"Content to Search\": \"Plasma concentration ranges or AUC data for simvastatin in CYP3A5 normal metabolizers.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What do the SLC6A4 'l' and 's' alleles refer to in the context of the 5-HTTLPR polymorphism?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"vortioxetine\", \"Gene Name\": \"SLC6A4\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf\", \"Content to Search\": \"Definition of the long and short alleles of the SLC6A4 gene promoter polymorphism (5-HTTLPR).\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of the CYP2B6 enzyme in the metabolism of fluvoxamine?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"fluvoxamine\", \"Gene Name\": \"CYP2B6\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf\", \"Content to Search\": \"Description of CYP2B6's role in the metabolic pathway of fluvoxamine.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the target plasma concentrations of regorafenib's active metabolites (M-2 and M-5) in a patient with a high-activity UGT1A9 genotype?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the dosing recommendation for naltrexone in children with a CYP2D6 poor metabolizer phenotype?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"naltrexone\", \"Gene Name\": \"CYP2D6\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf\", \"Content to Search\": \"Pediatric dosing adjustments for naltrexone in CYP2D6 poor metabolizers.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the dosing recommendation for moxifloxacin in a pediatric patient with G6PD deficiency?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"moxifloxacin\", \"Gene Name\": \"G6PD\", \"CPIC Guideline Name\": \"Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf\", \"Content to Search\": \"Pediatric-specific dosing guidelines for moxifloxacin in G6PD deficient children.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the suggested therapeutic effect for quinapril based on a patient's ACE genotype?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the quantified risk of acute hemolytic anemia for a G6PD deficient individual taking trametinib?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"trametinib\", \"Gene Name\": \"G6PD\", \"CPIC Guideline Name\": \"Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf\", \"Content to Search\": \"Incidence rates or risk multipliers for acute hemolytic anemia with trametinib use in G6PD deficient patients.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of developing a rash with lamotrigine in individuals with low-activity UGT1A4 variants?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the target plasma concentrations for memantine in a patient with a high-function SLC22A2 transporter?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the suggested therapeutic range for plasma 5-FU concentrations in a capecitabine-treated patient based on their CES2 genotype?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended dose of cisplatin for a patient with a specific variant in the ERCC1 gene?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the mechanism by which KCNH2 variants increase the risk of dofetilide-induced Torsades de Pointes?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How should bisoprolol dosing be adjusted for a CYP2D6 poor metabolizer?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"bisoprolol\", \"Gene Name\": \"CYP2D6\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Dose adjustment protocol for bisoprolol in CYP2D6 poor metabolizers.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "Does the presence of the HLA-B*15:02 allele have the same predictive value for oxcarbazepine as it does for carbamazepine?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"oxcarbazepine\", \"Gene Name\": \"HLA-B\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for HLA Genotype and Use of Carbamazepine and Oxcarbazepine: 2017 Update (December 2017).pdf\", \"Content to Search\": \"Comparison of predictive value of HLA-B*15:02 for hypersensitivity between oxcarbazepine and carbamazepine\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of hyperphosphatemia and retinal pigment epithelial detachment with infigratinib in patients with reduced CYP3A4 function?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the dosing recommendation for fluoxetine in adolescents with the SLC6A4 S/S genotype?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"fluoxetine\", \"Gene Name\": \"SLC6A4\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf\", \"Content to Search\": \"Dosing guidelines for fluoxetine in adolescent patients, adjusted for SLC6A4 genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended rosuvastatin dose for a CYP3A5 poor metabolizer (non-expresser)?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"rosuvastatin\", \"Gene Name\": \"CYP3A5\", \"CPIC Guideline Name\": \"The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf\", \"Content to Search\": \"Dose adjustment protocol for rosuvastatin in CYP3A5 poor metabolizers.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the suggested therapeutic range for plasma sitagliptin concentrations in a patient with a high-function OAT3 genotype?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the dosing recommendation for buprenorphine in pediatric patients with a COMT low-activity genotype?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"buprenorphine\", \"Gene Name\": \"COMT\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf\", \"Content to Search\": \"Pediatric dosing guidelines for buprenorphine adjusted for COMT low-activity genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended lansoprazole dose for a CYP2C19 poor metabolizer?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"lansoprazole\", \"Gene Name\": \"CYP2C19\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C19 and Proton Pump Inhibitor Dosing (August 2020).pdf\", \"Content to Search\": \"Dose adjustment protocol for lansoprazole in CYP2C19 poor metabolizers.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the risk of behavioral side effects with levetiracetam in individuals with specific SV2A variants?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the risk of treatment resistance to cisplatin in non-small cell lung cancer patients with high ERCC1 expression?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How should vilazodone dosing be adjusted for an individual with the HTR2A rs6313 G/G genotype?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"vilazodone\", \"Gene Name\": \"HTR2A\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf\", \"Content to Search\": \"Dose adjustment protocol for vilazodone based on HTR2A rs6313 genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of the SLC6A4 gene product in the mechanism of action of escitalopram?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"escitalopram\", \"Gene Name\": \"SLC6A4\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf\", \"Content to Search\": \"Explanation of SLC6A4's role as the serotonin transporter, the primary target of escitalopram.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the mechanism by which dabrafenib causes oxidative stress leading to hemolysis in G6PD deficient individuals?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"dabrafenib\", \"Gene Name\": \"G6PD\", \"CPIC Guideline Name\": \"Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf\", \"Content to Search\": \"Biochemical mechanism of dabrafenib-induced oxidative damage to red blood cells in the context of G6PD deficiency.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the risk of non-response to sildenafil in individuals with specific variants in the phosphodiesterase type 5 (PDE5A) gene?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the risk of non-response for an individual with the HTR2A rs6313 G/G genotype taking vortioxetine?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"vortioxetine\", \"Gene Name\": \"HTR2A\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf\", \"Content to Search\": \"Quantified risk or odds ratio for treatment non-response in vortioxetine users with the HTR2A rs6313 G/G genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How do SLCO1B1 genotypes correlate with valsartan antihypertensive response phenotypes?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the dosing recommendation for remifentanil in children with a CYP2D6 ultrarapid metabolizer phenotype?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"remifentanil\", \"Gene Name\": \"CYP2D6\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf\", \"Content to Search\": \"Pediatric dosing adjustments for remifentanil in CYP2D6 ultrarapid metabolizers.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the mechanism by which pegloticase causes oxidative stress leading to hemolysis in G6PD deficient individuals?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"pegloticase\", \"Gene Name\": \"G6PD\", \"CPIC Guideline Name\": \"Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf\", \"Content to Search\": \"Biochemical mechanism of pegloticase-induced oxidative damage to red blood cells in the context of G6PD deficiency.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended dose of apixaban for a patient who is a CYP3A4 poor metabolizer?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of the SLCO1B1 transporter in the pharmacokinetics of pitavastatin?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"pitavastatin\", \"Gene Name\": \"SLCO1B1\", \"CPIC Guideline Name\": \"The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf\", \"Content to Search\": \"Description of SLCO1B1's role as a hepatic uptake transporter affecting pitavastatin clearance.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What G6PD genotypes are classified as deficient (e.g., Class I, II, or III variants)?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"pegloticase\", \"Gene Name\": \"G6PD\", \"CPIC Guideline Name\": \"Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf\", \"Content to Search\": \"Definitions of G6PD genotypes and their classification into different functional/phenotypic classes of deficiency.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the mechanism by which nitrofural causes oxidative stress leading to hemolysis in G6PD deficient individuals?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"nitrofural\", \"Gene Name\": \"G6PD\", \"CPIC Guideline Name\": \"Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf\", \"Content to Search\": \"Biochemical mechanism of nitrofural-induced oxidative damage to red blood cells in the context of G6PD deficiency.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of pancreatic lipase (PNLIP), the target of orlistat, and how might its variants alter drug binding?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of the CYP2B6 enzyme in the metabolism of citalopram?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"citalopram\", \"Gene Name\": \"CYP2B6\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf\", \"Content to Search\": \"Description of CYP2B6's role in the metabolic pathway of citalopram.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What ADRB1 genotypes are associated with enhanced beta-blocker response?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"labetalol\", \"Gene Name\": \"ADRB1\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Definitions of ADRB1 genotypes (e.g., Arg389Arg) and their association with increased beta-blocker efficacy.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of fatal hepatotoxicity with valproic acid in children with an underlying POLG1-related mitochondrial disorder?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of the CYP3A5 enzyme in the metabolism of lovastatin?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"lovastatin\", \"Gene Name\": \"CYP3A5\", \"CPIC Guideline Name\": \"The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf\", \"Content to Search\": \"Description of CYP3A5's role in lovastatin metabolism.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the target plasma concentrations for mirtazapine in a patient with a CYP2D6 ultrarapid metabolizer phenotype?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the expected plasma labetalol concentrations in a CYP2D6 ultrarapid metabolizer?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"labetalol\", \"Gene Name\": \"CYP2D6\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Plasma concentration ranges or AUC data for labetalol in CYP2D6 ultrarapid metabolizers.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the expected plasma concentration of the active metabolite of clopidogrel in a CYP2C19 ultrarapid metabolizer compared to a normal metabolizer?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"clopidogrel\", \"Gene Name\": \"CYP2C19\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2C19 Genotype and Clopidogrel Therapy: 2022 update (January 2022).pdf\", \"Content to Search\": \"Pharmacokinetic data comparing active metabolite concentrations of clopidogrel across CYP2C19 phenotypes.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How do ABCB1 genotypes correlate with the risk of CNS side effects from standard doses of loperamide?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How do NRAS mutational statuses correlate with panitumumab resistance phenotypes?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of the CYP2D6 enzyme in the metabolism of citalopram?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"citalopram\", \"Gene Name\": \"CYP2D6\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf\", \"Content to Search\": \"Description of CYP2D6's role in the metabolic pathway of citalopram.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of the CYP3A4 enzyme in the extensive first-pass metabolism of budesonide?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended starting dose of imipramine for a CYP2D6 poor metabolizer?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"imipramine\", \"Gene Name\": \"CYP2D6\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC®) for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants: 2016 Update (December 2016).pdf\", \"Content to Search\": \"Recommended starting dose for imipramine in CYP2D6 poor metabolizers\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the dosing recommendation for dimercaprol in a G6PD deficient patient being treated for heavy metal poisoning?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"dimercaprol\", \"Gene Name\": \"G6PD\", \"CPIC Guideline Name\": \"Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf\", \"Content to Search\": \"Dosing guidelines for dimercaprol in G6PD deficient patients with heavy metal poisoning.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the dosing recommendation for citalopram in pediatric patients with a CYP2B6 poor metabolizer phenotype?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"citalopram\", \"Gene Name\": \"CYP2B6\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf\", \"Content to Search\": \"Pediatric dosing adjustments for citalopram in CYP2B6 poor metabolizers.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the dosing recommendation for teriflunomide in multiple sclerosis patients with a known CYP2C8*3 allele?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How do IL2RA genotypes correlate with IL-2 efficacy and toxicity phenotypes?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended dosing for enflurane in a patient with a RYR1 genotype conferring Malignant Hyperthermia Susceptibility?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"enflurane\", \"Gene Name\": \"RYR1\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for the use of potent volatile anesthetic agents and succinylcholine in the context of RYR1 or CACNA1S genotypes.pdf\", \"Content to Search\": \"Dosing protocol or avoidance recommendation for enflurane in patients with RYR1-Malignant Hyperthermia Susceptibility.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How do NPC1L1 genotypes correlate with ezetimibe efficacy phenotypes?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of the HTR2A gene product in the mechanism of action of vilazodone?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"vilazodone\", \"Gene Name\": \"HTR2A\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf\", \"Content to Search\": \"Description of the 5-HT2A receptor's role in antidepressant response and as a potential pharmacodynamic factor for vilazodone.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the role of the CYP2C9 enzyme in the metabolism of lumiracoxib?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"lumiracoxib\", \"Gene Name\": \"CYP2C9\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf\", \"Content to Search\": \"Description of CYP2C9's function in lumiracoxib's metabolic pathway.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How is warfarin dosing adjusted for an elderly patient with a sensitive VKORC1 genotype?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"warfarin\", \"Gene Name\": \"VKORC1\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for Pharmacogenetics-guided Warfarin Dosing: 2016 Update.pdf\", \"Content to Search\": \"Dosing recommendations for warfarin in elderly patients with a sensitive VKORC1 genotype\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the role of the CYP2C9 enzyme in the metabolism of tenoxicam?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"tenoxicam\", \"Gene Name\": \"CYP2C9\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf\", \"Content to Search\": \"Description of CYP2C9's function in tenoxicam's metabolic pathway.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How should propranolol dosing be adjusted for a patient with a TPMT poor metabolizer phenotype?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the target plasma concentrations for aprepitant in a CYP3A4 poor metabolizer?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the suggested therapeutic range for plasma atorvastatin concentrations in a CYP3A4 rapid metabolizer?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the mechanism by which doxorubicin causes oxidative stress leading to hemolysis in G6PD deficient individuals?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"doxorubicin\", \"Gene Name\": \"G6PD\", \"CPIC Guideline Name\": \"Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf\", \"Content to Search\": \"Biochemical mechanism of doxorubicin-induced oxidative damage to red blood cells in the context of G6PD deficiency.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the expected hematological changes in a G6PD deficient individual exposed to glyburide?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"glyburide\", \"Gene Name\": \"G6PD\", \"CPIC Guideline Name\": \"Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf\", \"Content to Search\": \"Data on hematological parameters in G6PD deficient individuals after glyburide administration.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How should tenofovir disoproxil fumarate (TDF) dosing be adjusted for a patient with an ABCC2 variant?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of the CYP2C9 enzyme in the metabolism of warfarin?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"warfarin\", \"Gene Name\": \"CYP2C9\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for Pharmacogenetics-guided Warfarin Dosing: 2016 Update.pdf\", \"Content to Search\": \"Role of CYP2C9 in the metabolic pathway of S-warfarin\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the target plasma concentrations for letrozole in a patient with a CYP2A6 rapid metabolizer phenotype?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the dosing recommendation for codeine in pediatric patients with a COMT high-activity genotype?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"codeine\", \"Gene Name\": \"COMT\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf\", \"Content to Search\": \"Pediatric dosing guidelines for codeine adjusted for COMT high-activity genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "Are there combined CYP2C8 and CYP2C9 genotype considerations for celecoxib dosing?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"celecoxib\", \"Gene Name\": \"CYP2C8\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf\", \"Content to Search\": \"Guidance on combined CYP2C8/CYP2C9 genotypes for celecoxib therapy.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended dose reduction for nortriptyline in a CYP2D6 poor metabolizer?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"nortriptyline\", \"Gene Name\": \"CYP2D6\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC®) for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants: 2016 Update (December 2016).pdf\", \"Content to Search\": \"Specific dose reduction percentage for nortriptyline in CYP2D6 poor metabolizers\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of the IL5RA, the target of mepolizumab, and how do its variants alter drug binding?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "Which OPRM1 genotypes are associated with poor response phenotypes to sertraline therapy?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How should acebutolol dosing be adjusted for an individual with a GRK5 polymorphism associated with altered response?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"acebutolol\", \"Gene Name\": \"GRK5\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Dose adjustment protocol for acebutolol based on GRK5 genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the expected plasma hydromorphone concentrations in a patient with a COMT low-activity genotype?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"hydromorphone\", \"Gene Name\": \"COMT\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf\", \"Content to Search\": \"Therapeutic range or plasma concentration data for hydromorphone stratified by COMT genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the dosing recommendation for atenolol in elderly patients with a CYP2D6 poor metabolizer phenotype?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"atenolol\", \"Gene Name\": \"CYP2D6\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Dosing adjustments for atenolol in elderly CYP2D6 poor metabolizers.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What ADRB2 polymorphisms (e.g., Gly16Arg, Gln27Glu) are associated with altered beta-blocker response?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"sotalol\", \"Gene Name\": \"ADRB2\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Definitions of ADRB2 polymorphisms and their functional impact on beta-blocker therapy.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How should sildenafil dosing be adjusted for a patient with a PDE5A gene variant?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of cognitive impairment and congestive heart failure with entrectinib in individuals with reduced CYP3A4 function?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of the ADRB2 gene product in the context of carvedilol therapy?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"carvedilol\", \"Gene Name\": \"ADRB2\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Explanation of the role of the beta-2 adrenergic receptor and its interaction with carvedilol.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of the IFNL3 gene that influences the efficacy of peginterferon alfa-2a in treating Hepatitis C?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"peginterferon alfa-2a\", \"Gene Name\": \"IFNL3\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for IFNL3 (IL28B) Genotype and PEG interferon-alpha-based Regimens (February 2014).pdf\", \"Content to Search\": \"Role of the IFNL3 gene product in the immune response to HCV and interferon-based therapy\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the suggested plasma concentration limits for amphotericin B based on a patient's genetic risk score for kidney injury?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the expected hematological changes, such as hemoglobin drop, in a G6PD deficient individual exposed to aminosalicylic acid?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"aminosalicylic acid\", \"Gene Name\": \"G6PD\", \"CPIC Guideline Name\": \"Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf\", \"Content to Search\": \"Data on hematological parameters (hemoglobin, reticulocyte count) in G6PD deficient individuals after aminosalicylic acid administration.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What diplotypes define a CYP3A4 intermediate metabolizer for amlodipine therapy?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What do the SLC6A4 'l' and 's' alleles refer to in the context of the 5-HTTLPR polymorphism?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"sertraline\", \"Gene Name\": \"SLC6A4\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf\", \"Content to Search\": \"Definition of the long and short alleles of the SLC6A4 gene promoter polymorphism (5-HTTLPR).\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How should semaglutide dosing be adjusted for a patient with a specific variant in the GLP-1 receptor (GLP1R) gene?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How should olanzapine dosing be adjusted for a patient with a UGT1A4*3 allele?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the expected hematological changes in a G6PD deficient individual exposed to primaquine?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"primaquine\", \"Gene Name\": \"G6PD\", \"CPIC Guideline Name\": \"Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf\", \"Content to Search\": \"Data on hematological parameters in G6PD deficient individuals after primaquine administration.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How do CYP2C9 genotypes map to gliclazide clearance phenotypes?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the risk of a blunted heart rate response to metoprolol in individuals homozygous for the ADRB1 Gly49 variant?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the expected clinical response to desvenlafaxine in a patient with the SLC6A4 L/S genotype?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"desvenlafaxine\", \"Gene Name\": \"SLC6A4\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf\", \"Content to Search\": \"Pharmacodynamic data, such as remission rates, for desvenlafaxine stratified by SLC6A4 5-HTTLPR genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the role of the COMT enzyme in the pharmacological response to tramadol?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"tramadol\", \"Gene Name\": \"COMT\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf\", \"Content to Search\": \"Mechanism of interaction between COMT enzyme activity and tramadol's effects.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the suggested plasma concentration limits for bleomycin based on a patient's BLMH genotype?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "Which CYP2D6 diplotypes define a normal metabolizer for the purpose of granisetron therapy?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How should vortioxetine dosing be adjusted for a CYP2C19 poor metabolizer?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"vortioxetine\", \"Gene Name\": \"CYP2C19\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf\", \"Content to Search\": \"Dose adjustment protocol for vortioxetine in CYP2C19 poor metabolizers.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the target plasma concentrations for pitavastatin in a patient with a high-activity UGT1A3 genotype?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What diplotypes define a CYP3A4 normal metabolizer?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"rosuvastatin\", \"Gene Name\": \"CYP3A4\", \"CPIC Guideline Name\": \"The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf\", \"Content to Search\": \"Diplotype definitions and activity scores for the CYP3A4 normal metabolizer phenotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What GRK5 polymorphisms are associated with altered beta-blocker response?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"carvedilol\", \"Gene Name\": \"GRK5\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Definitions of GRK5 variants (e.g., Gln41Leu) and their association with beta-blocker efficacy.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What diplotypes define a CYP3A4 intermediate metabolizer for alprazolam therapy?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the expected pharmacodynamic effects on blood pressure in a patient with a low-activity GRK4 variant taking nebivolol?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"nebivolol\", \"Gene Name\": \"GRK4\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Pharmacodynamic data for nebivolol stratified by GRK4 genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "Are there combined CYP2C8 and CYP2C9 genotype considerations for aspirin dosing in any special population?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"aspirin\", \"Gene Name\": \"CYP2C9\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf\", \"Content to Search\": \"Guidance on combined CYP2C8/CYP2C9 genotypes for aspirin therapy in special populations.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "Which OPRM1 genotypes are associated with poor response phenotypes to escitalopram therapy?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How do theoretical genotypes map to guaifenesin clearance phenotypes?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What diplotypes define a CYP2C9 poor metabolizer?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"phenytoin\", \"Gene Name\": \"CYP2C9\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP2C9 and HLA-B Genotype and Phenytoin Dosing (August 2020).pdf\", \"Content to Search\": \"Diplotype definitions for the CYP2C9 poor metabolizer phenotype\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of the SLCO1B1 transporter in the pharmacokinetics of pravastatin?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"pravastatin\", \"Gene Name\": \"SLCO1B1\", \"CPIC Guideline Name\": \"The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf\", \"Content to Search\": \"Description of SLCO1B1's role as a hepatic uptake transporter affecting pravastatin clearance.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What do the SLC6A4 'l' and 's' alleles refer to in the context of the 5-HTTLPR polymorphism?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"vilazodone\", \"Gene Name\": \"SLC6A4\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf\", \"Content to Search\": \"Definition of the long and short alleles of the SLC6A4 gene promoter polymorphism (5-HTTLPR).\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How do DCK genotypes map to cladribine activation phenotypes?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "Is a dose adjustment for indomethacin recommended based on CYP2C8 genotype?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"indomethacin\", \"Gene Name\": \"CYP2C8\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf\", \"Content to Search\": \"Dose adjustment protocol for indomethacin based on CYP2C8 genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of the BCHE enzyme in the metabolism of rivastigmine?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How do ATM genotypes correlate with metformin efficacy phenotypes?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the dosing recommendation for amlodipine in pediatric patients with known CYP3A4 variants?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What OPRM1 variants are associated with altered codeine response?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"codeine\", \"Gene Name\": \"OPRM1\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf\", \"Content to Search\": \"List and description of OPRM1 variants and their corresponding functional impact on codeine response.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of the Synaptic Vesicle Glycoprotein 2A (SV2A), the binding site for levetiracetam, and how do its variants alter drug affinity?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How does the CYP2C8*3 allele affect the pharmacokinetics of aspirin?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"aspirin\", \"Gene Name\": \"CYP2C8\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf\", \"Content to Search\": \"Pharmacokinetic data on aspirin exposure related to the CYP2C8*3 allele.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "Is there a correlation between IFNL4 genotype and the therapeutic plasma concentration of ribavirin?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"ribavirin\", \"Gene Name\": \"IFNL4\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for IFNL3 (IL28B) Genotype and PEG interferon-alpha-based Regimens (February 2014).pdf\", \"Content to Search\": \"Pharmacokinetic data on ribavirin concentrations stratified by IFNL4 genotype\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of CYP2D6 in the 5-hydroxylation of propafenone?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What diplotypes for CYP3A4 and CYP1A2 define a poor metabolizer phenotype for ziprasidone therapy?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the expected plasma concentrations of desvenlafaxine in a CYP2C19 ultrarapid metabolizer?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"desvenlafaxine\", \"Gene Name\": \"CYP2C19\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf\", \"Content to Search\": \"Plasma concentration ranges or AUC data for desvenlafaxine in CYP2C19 ultrarapid metabolizers.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of the ADRB2 gene product in the context of nebivolol therapy?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"nebivolol\", \"Gene Name\": \"ADRB2\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Explanation of ADRB2's role as the beta-2 adrenergic receptor and its relevance to nebivolol therapy.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended dose of amoxicillin for a patient with a specific penicillin-binding protein (PBP) gene variant?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the suggested CPK monitoring frequency for a daptomycin-treated patient based on their genetic risk score for myopathy?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What diplotypes define a CYP3A4 intermediate metabolizer for felodipine therapy?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of venous thromboembolism (VTE) in warfarin-treated patients who are heterozygous for Factor V Leiden?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of the OCT2 transporter (encoded by SLC22A2) in the elimination of memantine?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the role of the NKCC2 cotransporter (encoded by SLC12A1) as the direct target of furosemide?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the therapeutic range for the sum of doxepin and nordoxepin concentrations?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"doxepin\", \"Gene Name\": \"CYP2D6\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC®) for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants: 2016 Update (December 2016).pdf\", \"Content to Search\": \"Therapeutic drug monitoring range for doxepin plus its active metabolite\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the expected plasma rosuvastatin concentrations in an individual with ABCG2 decreased function?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"rosuvastatin\", \"Gene Name\": \"ABCG2\", \"CPIC Guideline Name\": \"The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf\", \"Content to Search\": \"Plasma concentration ranges or AUC data for rosuvastatin in individuals with ABCG2 decreased function.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the suggested therapeutic range for plasma lorlatinib concentrations in a CYP3A4 rapid metabolizer?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What diplotypes define a CYP2C9 poor metabolizer for torsemide therapy according to CPIC guidelines?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of the deiodinase, type 2 enzyme (DIO2) in the activation of thyroid hormone?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the role of the COMT enzyme in the pharmacological response to codeine?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"codeine\", \"Gene Name\": \"COMT\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf\", \"Content to Search\": \"Mechanism of interaction between COMT enzyme activity and codeine's effects.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the mechanism by which norfloxacin causes oxidative stress leading to hemolysis in G6PD deficient individuals?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"norfloxacin\", \"Gene Name\": \"G6PD\", \"CPIC Guideline Name\": \"Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf\", \"Content to Search\": \"Biochemical mechanism of norfloxacin-induced oxidative damage to red blood cells in the context of G6PD deficiency.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "Are there different carbamazepine recommendations for pediatric patients with the HLA-A*31:01 allele?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"carbamazepine\", \"Gene Name\": \"HLA-A\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for HLA Genotype and Use of Carbamazepine and Oxcarbazepine: 2017 Update (December 2017).pdf\", \"Content to Search\": \"Specific dosing or clinical recommendations for carbamazepine in pediatric HLA-A*31:01 carriers\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the dosing recommendation for pitavastatin in pediatric patients with an HMGCR variant associated with reduced statin response?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"pitavastatin\", \"Gene Name\": \"HMGCR\", \"CPIC Guideline Name\": \"The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf\", \"Content to Search\": \"Pediatric dosing adjustments for pitavastatin based on HMGCR genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of the CYP2C8 enzyme in the metabolic clearance of pioglitazone?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the dosing recommendation for levomethadone in patients with opioid use disorder and an OPRM1 variant associated with decreased receptor function?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"levomethadone\", \"Gene Name\": \"OPRM1\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf\", \"Content to Search\": \"Dosing guidelines for levomethadone in opioid use disorder patients, adjusted for OPRM1 genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the suggested therapeutic range for plasma methadone concentrations in a CYP2B6 rapid metabolizer?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How should labetalol dosing be adjusted for an individual with an ADRA2C polymorphism associated with altered response?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"labetalol\", \"Gene Name\": \"ADRA2C\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Dose adjustment protocol for labetalol based on ADRA2C genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "Is a dose adjustment for low-dose aspirin recommended based on CYP2C9 genotype for cardioprotection?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"aspirin\", \"Gene Name\": \"CYP2C9\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf\", \"Content to Search\": \"Dosing recommendations for low-dose aspirin based on CYP2C9 status.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the quantified risk of adverse outcomes in heart failure for an individual with the GRK5 Leu41 variant when taking pindolol?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"pindolol\", \"Gene Name\": \"GRK5\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Risk multipliers or clinical data on heart failure outcomes with pindolol in patients with the GRK5 Leu41 variant.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the target platelet reactivity unit (PRU) for a prasugrel-treated patient based on their PON1 genotype?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the quantified risk of altered therapeutic response for an individual with the ADRB2 Gly16Arg polymorphism taking esmolol?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"esmolol\", \"Gene Name\": \"ADRB2\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Quantified risk data for altered efficacy in individuals with the ADRB2 Gly16Arg polymorphism taking esmolol.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of cerebellar toxicity with high-dose cytarabine in individuals with low-activity CDA variants?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "Is there a recommended therapeutic range for trimipramine concentrations?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"trimipramine\", \"Gene Name\": \"CYP2D6\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC®) for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants: 2016 Update (December 2016).pdf\", \"Content to Search\": \"Therapeutic drug monitoring range for trimipramine\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of hypertension, diarrhea, and fatigue with cabozantinib in individuals with reduced CYP3A4 function?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the dosing recommendation for bisoprolol in patients with heart failure and an ADRA2C polymorphism associated with altered response?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"bisoprolol\", \"Gene Name\": \"ADRA2C\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Dosing guidelines for bisoprolol in heart failure patients, adjusted for ADRA2C genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended starting dose of warfarin for a patient with the VKORC1 -1639G>A (AA) genotype, indicating increased sensitivity?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"warfarin\", \"Gene Name\": \"VKORC1\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for Pharmacogenetics-guided Warfarin Dosing: 2016 Update.pdf\", \"Content to Search\": \"Specific starting dose or dose reduction percentage for warfarin in patients with VKORC1 -1639G>A (AA) genotype\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the dosing recommendation for sulfadimidine in a pediatric patient with G6PD deficiency?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"sulfadimidine\", \"Gene Name\": \"G6PD\", \"CPIC Guideline Name\": \"Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf\", \"Content to Search\": \"Pediatric-specific dosing guidelines for sulfadimidine in G6PD deficient children.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the quantified risk of ototoxicity when administering netilmicin to a patient with a pathogenic MT-RNR1 variant?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"netilmicin\", \"Gene Name\": \"MT-RNR1\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for MT-RNR1 and Aminoglycosides (May 2021).pdf\", \"Content to Search\": \"Incidence rates or risk multipliers for netilmicin-induced ototoxicity in MT-RNR1 variant carriers.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the expected hematological changes in a G6PD deficient individual exposed to tolbutamide?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"tolbutamide\", \"Gene Name\": \"G6PD\", \"CPIC Guideline Name\": \"Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf\", \"Content to Search\": \"Data on hematological parameters in G6PD deficient individuals after tolbutamide administration.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What genotypes define the COMT 'low-activity' phenotype?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"alfentanil\", \"Gene Name\": \"COMT\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf\", \"Content to Search\": \"Genotype definitions and corresponding diplotypes for the COMT low-activity phenotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended lovastatin dose for an individual with an HMGCR variant associated with reduced statin response?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"lovastatin\", \"Gene Name\": \"HMGCR\", \"CPIC Guideline Name\": \"The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf\", \"Content to Search\": \"Dose adjustment protocol for lovastatin based on HMGCR genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What diplotypes define a CYP2D6 ultrarapid metabolizer?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"alfentanil\", \"Gene Name\": \"CYP2D6\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf\", \"Content to Search\": \"Diplotype definitions and activity scores for the CYP2D6 ultrarapid metabolizer phenotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of SAMS for a CYP3A4 poor metabolizer taking atorvastatin?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"atorvastatin\", \"Gene Name\": \"CYP3A4\", \"CPIC Guideline Name\": \"The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf\", \"Content to Search\": \"Quantified risk data for SAMS in CYP3A4 poor metabolizers using atorvastatin.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended dose of olmesartan for a patient with a specific variant in the CES1 gene?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the suggested therapeutic response metric for zoledronic acid in bone metastases based on a patient's FDPS genotype?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How should venlafaxine dosing be adjusted for an individual with the SLC6A4 l/l genotype?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"venlafaxine\", \"Gene Name\": \"SLC6A4\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf\", \"Content to Search\": \"Dose adjustment protocol for venlafaxine based on SLC6A4 5-HTTLPR genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of respiratory depression with buprenorphine in individuals with reduced CYP3A4 function, especially when combined with benzodiazepines?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What diplotypes define a CYP2B6 poor metabolizer?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"paroxetine\", \"Gene Name\": \"CYP2B6\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf\", \"Content to Search\": \"Diplotype definitions and activity scores for the CYP2B6 poor metabolizer phenotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended initial fosphenytoin dose for an adult who is a CYP2C9 intermediate metabolizer?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"fosphenytoin\", \"Gene Name\": \"CYP2C9\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP2C9 and HLA-B Genotype and Phenytoin Dosing (August 2020).pdf\", \"Content to Search\": \"Dose adjustment protocol for fosphenytoin in CYP2C9 intermediate metabolizers\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the mechanism by which sulfamethoxazole causes oxidative stress leading to hemolysis in G6PD deficient individuals?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"sulfamethoxazole / trimethoprim\", \"Gene Name\": \"G6PD\", \"CPIC Guideline Name\": \"Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf\", \"Content to Search\": \"Biochemical mechanism of sulfamethoxazole-induced oxidative damage to red blood cells in the context of G6PD deficiency.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What G6PD genotypes are classified as deficient (e.g., Class I, II, or III variants)?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"glyburide\", \"Gene Name\": \"G6PD\", \"CPIC Guideline Name\": \"Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf\", \"Content to Search\": \"Definitions of G6PD genotypes and their classification into different functional/phenotypic classes of deficiency.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the mechanism by which nicorandil causes oxidative stress leading to hemolysis in G6PD deficient individuals?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"nicorandil\", \"Gene Name\": \"G6PD\", \"CPIC Guideline Name\": \"Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf\", \"Content to Search\": \"Biochemical mechanism of nicorandil-induced oxidative damage to red blood cells in the context of G6PD deficiency.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended nebivolol dose for an individual with the ADRB2 Gly16Arg polymorphism?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"nebivolol\", \"Gene Name\": \"ADRB2\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Dose adjustment protocol for nebivolol based on ADRB2 Gly16Arg genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of the ADRB2 gene product in the context of metoprolol therapy?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"metoprolol\", \"Gene Name\": \"ADRB2\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Explanation of ADRB2's role as the beta-2 adrenergic receptor and its relevance to beta-blocker side effects and efficacy.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How does the presence of the CYP4F2*3 allele influence the stable maintenance dose of warfarin?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"warfarin\", \"Gene Name\": \"CYP4F2\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for Pharmacogenetics-guided Warfarin Dosing: 2016 Update.pdf\", \"Content to Search\": \"Percentage or numerical dose adjustment for warfarin in carriers of the CYP4F2*3 allele\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended dose of temsirolimus for a patient who is a CYP3A4 poor metabolizer?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the target urinary sodium excretion for a bumetanide-treated patient based on their SLC12A1 genotype?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "Is quinine contraindicated or should dosing be adjusted for a G6PD deficient individual?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"quinine\", \"Gene Name\": \"G6PD\", \"CPIC Guideline Name\": \"Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf\", \"Content to Search\": \"Dosing protocol or contraindication for quinine in G6PD deficient individuals.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How does the CYP2C8*3 allele affect the pharmacokinetics of indomethacin?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"indomethacin\", \"Gene Name\": \"CYP2C8\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf\", \"Content to Search\": \"Pharmacokinetic data on indomethacin exposure related to the CYP2C8*3 allele.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the dosing recommendation for venlafaxine in a pediatric patient with a CYP2D6 poor metabolizer phenotype?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"venlafaxine\", \"Gene Name\": \"CYP2D6\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf\", \"Content to Search\": \"Pediatric dosing adjustments for venlafaxine in CYP2D6 poor metabolizers.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "Are there specific PK/PD parameters to monitor for enflurane in a patient with CACNA1S-related Malignant Hyperthermia Susceptibility?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"enflurane\", \"Gene Name\": \"CACNA1S\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for the use of potent volatile anesthetic agents and succinylcholine in the context of RYR1 or CACNA1S genotypes.pdf\", \"Content to Search\": \"Pharmacokinetic or pharmacodynamic monitoring parameters for enflurane in the context of CACNA1S-MHS.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What GRK4 polymorphisms are associated with altered beta-blocker response?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"sotalol\", \"Gene Name\": \"GRK4\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Definitions of GRK4 polymorphisms and their functional impact on beta-blocker therapy.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What diplotypes define a CYP3A4 normal metabolizer?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"pitavastatin\", \"Gene Name\": \"CYP3A4\", \"CPIC Guideline Name\": \"The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf\", \"Content to Search\": \"Diplotype definitions and activity scores for the CYP3A4 normal metabolizer phenotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the target serum urate levels for an allopurinol-treated patient based on their ABCG2 genotype?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How do FCGR2A genotypes correlate with trastuzumab-mediated ADCC and clinical outcomes?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the target fetal hemoglobin (HbF) level for a hydroxyurea-treated patient based on their genetic profile?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the primary metabolic pathway for quetiapine involving the CYP3A4 enzyme?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the suggested therapeutic range for plasma fluconazole concentrations in a CYP2C9 intermediate metabolizer?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of the CYP3A4 enzyme in the metabolism of the ROS1/TRK inhibitor entrectinib?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How do CYP2C8 genotypes map to teriflunomide clearance phenotypes?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the suggested therapeutic range for plasma oxymorphone concentrations (from oxycodone) in a patient with an OPRM1 variant leading to increased receptor expression?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"oxycodone\", \"Gene Name\": \"OPRM1\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf\", \"Content to Search\": \"Therapeutic drug monitoring values for oxymorphone (active metabolite of oxycodone) stratified by OPRM1 genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How does the IFNL4 genotype contribute to the overall response prediction for peginterferon/ribavirin therapy?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"ribavirin\", \"Gene Name\": \"IFNL4\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for IFNL3 (IL28B) Genotype and PEG interferon-alpha-based Regimens (February 2014).pdf\", \"Content to Search\": \"Definition of response phenotypes for combination therapy based on IFNL4 genotype\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How does the APOE genotype correlate with warfarin dose requirement phenotypes?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the expected plasma concentrations of paroxetine in a CYP2B6 ultrarapid metabolizer?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"paroxetine\", \"Gene Name\": \"CYP2B6\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf\", \"Content to Search\": \"Plasma concentration ranges or AUC data for paroxetine in CYP2B6 ultrarapid metabolizers.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of the HTR2A gene product in the context of duloxetine therapy?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"duloxetine\", \"Gene Name\": \"HTR2A\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf\", \"Content to Search\": \"Explanation of HTR2A's role as a serotonin receptor influencing the pharmacodynamic effects of duloxetine.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the risk of non-response to panitumumab in colorectal cancer patients with an NRAS Q61K mutation?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How should citalopram dosing be adjusted for an individual with the HTR2A rs7997012 A/A genotype?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"citalopram\", \"Gene Name\": \"HTR2A\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf\", \"Content to Search\": \"Dosing or therapeutic recommendations for citalopram based on HTR2A rs7997012 genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of the CYP2B6 enzyme in the metabolism of sertraline?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"sertraline\", \"Gene Name\": \"CYP2B6\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf\", \"Content to Search\": \"Description of CYP2B6's role in sertraline metabolism.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How should cisplatin dosing be adjusted for a patient with the COMT Val158Met polymorphism?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What diplotypes for CYP2C9 define a poor metabolizer in the context of tamoxifen therapy?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of the GRK5 gene product in the context of betaxolol therapy?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"betaxolol\", \"Gene Name\": \"GRK5\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Explanation of the role of G protein-coupled receptor kinase 5 in adrenergic receptor desensitization.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "Is trametinib contraindicated or should dosing be adjusted for a G6PD deficient individual?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"trametinib\", \"Gene Name\": \"G6PD\", \"CPIC Guideline Name\": \"Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf\", \"Content to Search\": \"Dosing protocol or contraindication for trametinib in G6PD deficient individuals.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended lovastatin dose for a CYP3A4 poor metabolizer?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"lovastatin\", \"Gene Name\": \"CYP3A4\", \"CPIC Guideline Name\": \"The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf\", \"Content to Search\": \"Dose adjustment protocol for lovastatin in CYP3A4 poor metabolizers.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of hyperkalemia with trimethoprim in individuals with low-function MATE1 transporter variants?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How should rivaroxaban dosing be adjusted for a patient with a low-function ABCB1 genotype?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of tachyphylaxis with albuterol in individuals with the ADRB2 Gly16 variant?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How do MAOA genotypes correlate with the risk of linezolid-induced hypertension?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the anesthetic recommendations for a pediatric patient with a RYR1 genotype conferring Malignant Hyperthermia Susceptibility?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"succinylcholine\", \"Gene Name\": \"RYR1\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for the use of potent volatile anesthetic agents and succinylcholine in the context of RYR1 or CACNA1S genotypes.pdf\", \"Content to Search\": \"Anesthetic agent selection and dosing for pediatric patients with RYR1-MHS.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the dosing recommendation for milnacipran in an elderly patient with a CYP2C19 poor metabolizer phenotype?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"milnacipran\", \"Gene Name\": \"CYP2C19\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf\", \"Content to Search\": \"Dosing adjustments for milnacipran in elderly CYP2C19 poor metabolizers.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the contribution of CYP2C8 to the overall clearance of lornoxicam?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"lornoxicam\", \"Gene Name\": \"CYP2C8\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf\", \"Content to Search\": \"Description of CYP2C8's role in lornoxicam's metabolic pathway.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of adverse effects for a CYP2C19 poor metabolizer taking levomilnacipran?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"levomilnacipran\", \"Gene Name\": \"CYP2C19\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf\", \"Content to Search\": \"Quantified risk data for adverse effects in CYP2C19 poor metabolizers using levomilnacipran.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the suggested therapeutic range for plasma efavirenz concentrations to minimize toxicity?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"efavirenz\", \"Gene Name\": \"CYP2B6\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2B6 and Efavirenz-containing Antiretroviral Therapy (April 2019).pdf\", \"Content to Search\": \"Therapeutic window or plasma concentration range for efavirenz.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What diplotypes define a CYP3A4 intermediate metabolizer for dasatinib therapy?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What HTR2A variants are associated with altered levomilnacipran response?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"levomilnacipran\", \"Gene Name\": \"HTR2A\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf\", \"Content to Search\": \"List and description of HTR2A variants and their corresponding impact on levomilnacipran response.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommendation for using methylene blue to treat methemoglobinemia in a G6PD deficient patient?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"methylene blue\", \"Gene Name\": \"G6PD\", \"CPIC Guideline Name\": \"Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf\", \"Content to Search\": \"Guidelines for methylene blue use for methemoglobinemia in G6PD deficient patients, including potential for paradoxical worsening.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the mercaptopurine dosing recommendation for a pediatric ALL patient who is a NUDT15 poor metabolizer?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"mercaptopurine\", \"Gene Name\": \"NUDT15\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium Guidelines for thiopurine dosing based on TPMT and NUDT15 genotypes: 2018 Update (November 2018).pdf\", \"Content to Search\": \"Pediatric dosing guidance for mercaptopurine in ALL patients with NUDT15 poor metabolizer status\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of P-glycoprotein (ABCB1) in limiting the blood-brain barrier penetration of venlafaxine?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How should erythropoietin (EPO) dosing be adjusted for a patient with a specific variant in the EPOR (EPO receptor) gene?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "Which CYP2D6 diplotypes define a poor metabolizer for the purposes of nebivolol therapy according to CPIC?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of bleomycin hydrolase (BLMH) in the inactivation and detoxification of bleomycin?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the expected plasma lovastatin concentrations in an individual with SLCO1B1 intermediate function?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"lovastatin\", \"Gene Name\": \"SLCO1B1\", \"CPIC Guideline Name\": \"The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf\", \"Content to Search\": \"Plasma concentration ranges or AUC data for lovastatin in individuals with SLCO1B1 intermediate function.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended dose of vandetanib for a patient who is a CYP3A4 poor metabolizer?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What diplotypes define a CYP2D6 ultrarapid metabolizer?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"atomoxetine\", \"Gene Name\": \"CYP2D6\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 Genotype and Atomoxetine (February 2019).pdf\", \"Content to Search\": \"Diplotype definitions and corresponding activity scores for the CYP2D6 ultrarapid metabolizer phenotype\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How do UGT2B7 genotypes map to empagliflozin clearance phenotypes?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended remifentanil dose for an individual with a COMT low-activity genotype?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"remifentanil\", \"Gene Name\": \"COMT\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf\", \"Content to Search\": \"Dose adjustment protocol for remifentanil in individuals with a COMT low-activity genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of treatment failure with cyclophosphamide in individuals who are CYP2B6 poor metabolizers?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of the CYP2D6 enzyme in the metabolism of vilazodone?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"vilazodone\", \"Gene Name\": \"CYP2D6\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf\", \"Content to Search\": \"Description of CYP2D6's role in vilazodone metabolism.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the dosing recommendation for nebivolol in elderly patients with heart failure and the GRK5 Leu41 variant?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"nebivolol\", \"Gene Name\": \"GRK5\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Dosing guidelines for nebivolol in elderly heart failure patients, adjusted for GRK5 genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended dosing for gentamicin in an individual with a pathogenic MT-RNR1 variant?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"gentamicin\", \"Gene Name\": \"MT-RNR1\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for MT-RNR1 and Aminoglycosides (May 2021).pdf\", \"Content to Search\": \"Dosing recommendations or alternative therapies for gentamicin in patients with pathogenic MT-RNR1 variants.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the quantified risk of acute hemolytic anemia for a G6PD deficient individual taking glyburide?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"glyburide\", \"Gene Name\": \"G6PD\", \"CPIC Guideline Name\": \"Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf\", \"Content to Search\": \"Incidence rates or risk multipliers for acute hemolytic anemia with glyburide use in G6PD deficient patients.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of suicidal ideation with atomoxetine in pediatric patients who are CYP2D6 poor metabolizers?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of the CYP2C8 enzyme in the metabolic pathway of paclitaxel?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How should sunitinib dosing be adjusted for a patient who is a CYP3A4 poor metabolizer?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "Is a dose adjustment for naproxen recommended based on CYP2C8 genotype?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"naproxen\", \"Gene Name\": \"CYP2C8\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf\", \"Content to Search\": \"Dose adjustment protocol for naproxen based on CYP2C8 genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "Are there specific dosing recommendations for tegafur in elderly patients with reduced DPYD activity?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"tegafur\", \"Gene Name\": \"DPYD\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Dihydropyrimidine Dehydrogenase Genotype and Fluoropyrimidine Dosing: 2017 Update (October 2017).pdf\", \"Content to Search\": \"Dosing guidance for tegafur in elderly patients with DPYD intermediate or poor metabolizer status\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of the O-6-methylguanine-DNA methyltransferase (MGMT) enzyme in repairing DNA damage caused by temozolomide?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of Monoamine Oxidase A (MAOA) in the metabolism of catecholamines affected by pseudoephedrine?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the biological function of the protein encoded by IFNL4 that impacts peginterferon alfa-2b treatment outcome?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"peginterferon alfa-2b\", \"Gene Name\": \"IFNL4\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for IFNL3 (IL28B) Genotype and PEG interferon-alpha-based Regimens (February 2014).pdf\", \"Content to Search\": \"Function of the IFNL4 gene product and its role in interferon signaling\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What diplotypes define a CYP2D6 poor metabolizer for diphenhydramine therapy according to CPIC guidelines?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the expected hematological changes in a G6PD deficient individual exposed to glipizide?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"glipizide\", \"Gene Name\": \"G6PD\", \"CPIC Guideline Name\": \"Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf\", \"Content to Search\": \"Data on hematological parameters in G6PD deficient individuals after glipizide administration.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How do UGT1A1 genotypes correlate with nilotinib-induced liver toxicity and QTc prolongation?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of cough with benazepril in individuals with the ACE DD genotype?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How does mercaptopurine exert its cytotoxic effect, and how does NUDT15 activity mitigate this?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"mercaptopurine\", \"Gene Name\": \"NUDT15\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium Guidelines for thiopurine dosing based on TPMT and NUDT15 genotypes: 2018 Update (November 2018).pdf\", \"Content to Search\": \"Mechanism of action of mercaptopurine and the protective role of the NUDT15 enzyme\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended dosing adjustment for imipramine in a CYP2C19 ultrarapid metabolizer?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"imipramine\", \"Gene Name\": \"CYP2C19\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC®) for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants: 2016 Update (December 2016).pdf\", \"Content to Search\": \"Dose adjustment protocol for imipramine in CYP2C19 ultrarapid metabolizers\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended dose of ketorolac for a patient identified as a CYP2C9 poor metabolizer?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the dosing recommendation for escitalopram in pediatric patients with a CYP2C19 poor metabolizer phenotype?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"escitalopram\", \"Gene Name\": \"CYP2C19\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf\", \"Content to Search\": \"Pediatric dosing adjustments for escitalopram in CYP2C19 poor metabolizers.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How should theophylline dosing be adjusted for a patient who is a CYP2E1 rapid metabolizer?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the expected plasma concentrations of levomilnacipran in a CYP2B6 ultrarapid metabolizer?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"levomilnacipran\", \"Gene Name\": \"CYP2B6\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf\", \"Content to Search\": \"Plasma concentration ranges or AUC data for levomilnacipran in CYP2B6 ultrarapid metabolizers.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How do MT-RNR1 genotypes correlate with aminoglycoside-induced ototoxicity phenotypes?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How should selegiline dosing be adjusted for a patient who is a CYP2B6 poor metabolizer?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How should propafenone dosing be adjusted for a patient who is a CYP2D6 poor metabolizer?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of the Niemann-Pick C1-Like 1 (NPC1L1) protein, the direct target of ezetimibe, and how do its variants alter drug action?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "Which diplotypes define a TPMT intermediate metabolizer?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"azathioprine\", \"Gene Name\": \"TPMT\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium Guidelines for thiopurine dosing based on TPMT and NUDT15 genotypes: 2018 Update (November 2018).pdf\", \"Content to Search\": \"Diplotype definitions for the TPMT intermediate metabolizer phenotype\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the suggested therapeutic range for plasma clindamycin concentrations in a CYP3A4 rapid metabolizer?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "Is sodium nitrite contraindicated or should dosing be adjusted for a G6PD deficient individual?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"sodium nitrite\", \"Gene Name\": \"G6PD\", \"CPIC Guideline Name\": \"Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf\", \"Content to Search\": \"Dosing protocol or contraindication for sodium nitrite in G6PD deficient individuals.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended codeine dose for a CYP2D6 ultrarapid metabolizer?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"codeine\", \"Gene Name\": \"CYP2D6\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf\", \"Content to Search\": \"Specific dosing recommendation or contraindication for codeine in CYP2D6 ultrarapid metabolizers.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of stomatitis and non-infectious pneumonitis with everolimus in individuals with reduced CYP3A4 function?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How do COMT genotypes correlate with levodopa response and the need for COMT inhibitors?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "Which KCNJ11 genotypes are associated with altered insulin secretion phenotypes?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What diplotypes define a CYP2C19 normal metabolizer?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"duloxetine\", \"Gene Name\": \"CYP2C19\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf\", \"Content to Search\": \"Diplotype definitions and activity scores for the CYP2C19 normal metabolizer phenotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the role of the CYP2C19 enzyme in the pharmacokinetics of milnacipran?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"milnacipran\", \"Gene Name\": \"CYP2C19\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf\", \"Content to Search\": \"Description of CYP2C19's role in milnacipran metabolism.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the risk of poor response to omeprazole in individuals with high-activity ABCB1 transporter variants?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended dose adjustment for tolterodine based on a patient's CYP2D6 ultrarapid metabolizer status?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of the ADRB1 gene product in the context of nebivolol therapy?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"nebivolol\", \"Gene Name\": \"ADRB1\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Explanation of ADRB1's role as the beta-1 adrenergic receptor, a primary target for nebivolol.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "Which RYR1 genotypes are associated with Malignant Hyperthermia Susceptibility?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"succinylcholine\", \"Gene Name\": \"RYR1\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for the use of potent volatile anesthetic agents and succinylcholine in the context of RYR1 or CACNA1S genotypes.pdf\", \"Content to Search\": \"Diplotype or allele definitions for RYR1 that correspond to the Malignant Hyperthermia Susceptible phenotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the dosing recommendation for betaxolol in patients with asthma and an ADRB2 polymorphism associated with altered response?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"betaxolol\", \"Gene Name\": \"ADRB2\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Dosing guidelines for betaxolol in asthmatic patients, adjusted for ADRB2 genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What diplotypes define a CYP2D6 poor metabolizer?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"levomilnacipran\", \"Gene Name\": \"CYP2D6\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf\", \"Content to Search\": \"Diplotype definitions and activity scores for the CYP2D6 poor metabolizer phenotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "Is furazolidone contraindicated or should dosing be adjusted for a G6PD deficient individual?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"furazolidone\", \"Gene Name\": \"G6PD\", \"CPIC Guideline Name\": \"Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf\", \"Content to Search\": \"Dosing protocol or contraindication for furazolidone in G6PD deficient individuals.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the role of UGT1A6 in the glucuronidation of the salicylate moiety from bismuth subsalicylate?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of Stevens-Johnson Syndrome with modafinil in individuals with specific HLA variants?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the quantified risk of myelosuppression in a TPMT poor metabolizer treated with a standard dose of azathioprine?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"azathioprine\", \"Gene Name\": \"TPMT\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium Guidelines for thiopurine dosing based on TPMT and NUDT15 genotypes: 2018 Update (November 2018).pdf\", \"Content to Search\": \"Incidence rate or risk multiplier for myelosuppression in TPMT poor metabolizers using azathioprine\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What G6PD genotypes are classified as deficient (e.g., Class I, II, or III variants)?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"aspirin\", \"Gene Name\": \"G6PD\", \"CPIC Guideline Name\": \"Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf\", \"Content to Search\": \"Definitions of G6PD genotypes and their classification into different functional/phenotypic classes of deficiency.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the expected plasma alfentanil concentrations in a patient with a COMT low-activity genotype?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"alfentanil\", \"Gene Name\": \"COMT\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf\", \"Content to Search\": \"Therapeutic range or plasma concentration data for alfentanil stratified by COMT genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of hepatotoxicity for a CYP2C19 poor metabolizer taking a standard dose of voriconazole?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"voriconazole\", \"Gene Name\": \"CYP2C19\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C19 and Voriconazole Therapy (December 2016).pdf\", \"Content to Search\": \"Quantified risk data for hepatotoxicity in CYP2C19 poor metabolizers using voriconazole.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How should ciclesonide dosing be adjusted for a patient with a specific CES2 variant?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the target plasma concentrations for ropinirole in a patient with a CYP1A2 rapid metabolizer phenotype?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of neutropenia with palbociclib in individuals with reduced CYP3A4 function?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the known functional classifications of CYP2C8 alleles relevant to NSAID metabolism?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"aceclofenac\", \"Gene Name\": \"CYP2C8\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf\", \"Content to Search\": \"Allele function table or definitions for CYP2C8.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of the CYP2C9 enzyme in the metabolic pathway of the Hedgehog pathway inhibitor vismodegib?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended dose of bevacizumab for a patient with a specific VEGF-A gene polymorphism?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the risk of angioedema from quinapril in individuals with the ACE DD genotype compared to the II genotype?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the suggested therapeutic range for plasma remifentanil concentrations in a patient with an OPRM1 variant leading to increased receptor expression?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"remifentanil\", \"Gene Name\": \"OPRM1\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf\", \"Content to Search\": \"Therapeutic drug monitoring values for remifentanil stratified by OPRM1 genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How should budesonide dosing be adjusted for a patient who is a CYP3A4 poor metabolizer?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the suggested plasma concentration ranges for atorvastatin in a DPYD intermediate metabolizer?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the dosing recommendation for nebivolol in geriatric patients with a CYP2D6 gene duplication?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of the CYP2C9 enzyme in the metabolic clearance of glipizide?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the risk of inadequate analgesia for individuals with the OPRM1 A118G variant when taking tramadol?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"tramadol\", \"Gene Name\": \"OPRM1\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf\", \"Content to Search\": \"Quantified risk or clinical evidence for reduced analgesic efficacy of tramadol in patients with the OPRM1 A118G variant.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What G6PD genotypes are classified as deficient (e.g., Class I, II, or III variants)?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"sodium nitrite\", \"Gene Name\": \"G6PD\", \"CPIC Guideline Name\": \"Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf\", \"Content to Search\": \"Definitions of G6PD genotypes and their classification into different functional/phenotypic classes of deficiency.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended sotalol dose for an individual with the ADRB2 Gly16Arg polymorphism?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"sotalol\", \"Gene Name\": \"ADRB2\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Dose adjustment protocol for sotalol based on ADRB2 Gly16Arg genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of the OATP1B1 transporter in the hepatic uptake of ceftriaxone?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What diplotypes define a CYP2D6 intermediate metabolizer?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"duloxetine\", \"Gene Name\": \"CYP2D6\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf\", \"Content to Search\": \"Diplotype definitions and activity scores for the CYP2D6 intermediate metabolizer phenotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the quantified risk of ototoxicity when administering neomycin to a patient with a pathogenic MT-RNR1 variant?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"neomycin\", \"Gene Name\": \"MT-RNR1\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for MT-RNR1 and Aminoglycosides (May 2021).pdf\", \"Content to Search\": \"Incidence rates or risk multipliers for neomycin-induced ototoxicity in MT-RNR1 variant carriers.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of gingival hyperplasia with felodipine in patients with reduced CYP3A4 function?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "Is nalidixic acid contraindicated or should dosing be adjusted for a G6PD deficient individual?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"nalidixic acid\", \"Gene Name\": \"G6PD\", \"CPIC Guideline Name\": \"Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf\", \"Content to Search\": \"Dosing protocol or contraindication for nalidixic acid in G6PD deficient individuals.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What genotypes define the COMT 'normal-activity' phenotype?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"codeine\", \"Gene Name\": \"COMT\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf\", \"Content to Search\": \"Genotype definitions and corresponding diplotypes for the COMT normal-activity phenotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the target level of free IgE for an omalizumab-treated patient based on their FCER1A genotype?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the suggested plasma aluminum concentration limits for a sucralfate-treated patient based on their genotype?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of severe myelosuppression with etoposide in individuals with specific ABCB1 variants?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the expected pharmacodynamic effects (e.g., change in blood pressure) in a patient with the ADRB2 Gln27Glu polymorphism taking acebutolol?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"acebutolol\", \"Gene Name\": \"ADRB2\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Pharmacodynamic data for acebutolol stratified by ADRB2 genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How should esmolol dosing be adjusted for an individual with an ADRA2C polymorphism associated with altered response?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"esmolol\", \"Gene Name\": \"ADRA2C\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Dose adjustment protocol for esmolol based on ADRA2C genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended pitavastatin dose for a CYP2C9 poor metabolizer?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"pitavastatin\", \"Gene Name\": \"CYP2C9\", \"CPIC Guideline Name\": \"The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf\", \"Content to Search\": \"Dose adjustment protocol for pitavastatin in CYP2C9 poor metabolizers.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What SLC6A4 variants (e.g., 5-HTTLPR) are associated with altered fluoxetine response?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"fluoxetine\", \"Gene Name\": \"SLC6A4\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf\", \"Content to Search\": \"List and description of SLC6A4 variants and their corresponding impact on fluoxetine response.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of bleeding with apixaban in individuals with reduced CYP3A4 function?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the suggested therapeutic effect measure for sertraline based on OPRM1 genotype?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of the CYP3A4 enzyme in the activation of ifosfamide?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the dosing recommendation for fluoxetine in adolescents with the HTR2A rs7997012 A/A genotype?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"fluoxetine\", \"Gene Name\": \"HTR2A\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf\", \"Content to Search\": \"Dosing guidelines for fluoxetine in adolescent patients, adjusted for HTR2A genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the suggested therapeutic range for plasma vandetanib concentrations in a CYP3A4 rapid metabolizer?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the dosing recommendation for valganciclovir (prodrug of ganciclovir) in transplant patients with known SLC22A6 variants?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How do UGT1A1 genotypes correlate with telmisartan clearance phenotypes?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the suggested therapeutic range for plasma 4-hydroxyifosfamide in a CYP3A4 rapid metabolizer?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How should terbinafine dosing be adjusted for a patient who is a CYP2D6 poor metabolizer?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the dosing recommendation for lovastatin in pediatric patients with ABCG2 decreased function?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"lovastatin\", \"Gene Name\": \"ABCG2\", \"CPIC Guideline Name\": \"The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf\", \"Content to Search\": \"Pediatric dosing guidelines for lovastatin adjusted for ABCG2 decreased function.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What diplotypes define a CYP2C19 poor metabolizer?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"fluoxetine\", \"Gene Name\": \"CYP2C19\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf\", \"Content to Search\": \"Diplotype definitions and activity scores for the CYP2C19 poor metabolizer phenotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of hydromorphone toxicity for a CYP2D6 ultrarapid metabolizer taking hydrocodone?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"hydrocodone\", \"Gene Name\": \"CYP2D6\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf\", \"Content to Search\": \"Quantified risk, incidence rate, or odds ratio for hydromorphone toxicity in CYP2D6 UMs using hydrocodone.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the mechanism by which glipizide causes oxidative stress leading to hemolysis in G6PD deficient individuals?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"glipizide\", \"Gene Name\": \"G6PD\", \"CPIC Guideline Name\": \"Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf\", \"Content to Search\": \"Biochemical mechanism of glipizide-induced oxidative damage to red blood cells in the context of G6PD deficiency.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of the ADRB2 gene product in the context of betaxolol therapy?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"betaxolol\", \"Gene Name\": \"ADRB2\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Explanation of the role of the beta-2 adrenergic receptor and its interaction with betaxolol.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of the CYP2D6 enzyme in the metabolism of pindolol?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"pindolol\", \"Gene Name\": \"CYP2D6\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Description of CYP2D6's role in pindolol metabolism.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of the CYP2C9 enzyme in the metabolism of lovastatin?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"lovastatin\", \"Gene Name\": \"CYP2C9\", \"CPIC Guideline Name\": \"The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf\", \"Content to Search\": \"Description of CYP2C9's role in lovastatin metabolism.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "Is rasburicase contraindicated or should dosing be adjusted for a G6PD deficient individual?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"rasburicase\", \"Gene Name\": \"G6PD\", \"CPIC Guideline Name\": \"Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf\", \"Content to Search\": \"Dosing protocol or contraindication for rasburicase in G6PD deficient individuals.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the target heart rate for a metoprolol-treated patient based on their ADRB1 genotype?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of peripheral neuropathy with bortezomib in individuals with specific PSMB5 variants?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended dose of escitalopram for a patient with the OPRM1 A118G variant?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the target FEV1 improvement for an ipratropium-treated patient based on their CHRM3 genotype?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the expected plasma concentrations of fluvoxamine in a CYP2C19 ultrarapid metabolizer?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"fluvoxamine\", \"Gene Name\": \"CYP2C19\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf\", \"Content to Search\": \"Plasma concentration ranges or AUC data for fluvoxamine in CYP2C19 ultrarapid metabolizers.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the expected plasma remifentanil concentrations in a patient with a COMT low-activity genotype?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"remifentanil\", \"Gene Name\": \"COMT\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf\", \"Content to Search\": \"Therapeutic range or plasma concentration data for remifentanil stratified by COMT genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What G6PD genotypes are classified as deficient (e.g., Class I, II, or III variants)?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"mepacrine\", \"Gene Name\": \"G6PD\", \"CPIC Guideline Name\": \"Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf\", \"Content to Search\": \"Definitions of G6PD genotypes and their classification into different functional/phenotypic classes of deficiency.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the risk of reduced therapeutic response for an individual homozygous for the ADRB1 Gly389 allele (Gly/Gly) when taking labetalol?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"labetalol\", \"Gene Name\": \"ADRB1\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Quantified risk data for reduced efficacy in ADRB1 Gly389/Gly389 individuals taking labetalol.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended dose of cyclophosphamide for a patient who is a CYP2B6 poor metabolizer?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How do SLC47A1 genotypes map to metformin renal excretion phenotypes?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended dose of lansoprazole for a patient who is a CYP2C19 ultrarapid metabolizer?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of P-glycoprotein (ABCB1) in the intestinal efflux of the direct renin inhibitor aliskiren?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How do CYP2D6 genotypes map to ranitidine metabolism phenotypes?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the target level of protein degradation for a pomalidomide-treated patient based on their CRBN genotype?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the role of the CYP2C19 enzyme in the demethylation of clomipramine?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"clomipramine\", \"Gene Name\": \"CYP2C19\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC®) for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants: 2016 Update (December 2016).pdf\", \"Content to Search\": \"Function of CYP2C19 in the metabolic pathway of clomipramine\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What G6PD genotypes are classified as deficient (e.g., Class I, II, or III variants)?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"glimepiride\", \"Gene Name\": \"G6PD\", \"CPIC Guideline Name\": \"Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf\", \"Content to Search\": \"Definitions of G6PD genotypes and their classification into different functional/phenotypic classes of deficiency.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of priapism with trazodone in patients with reduced CYP3A4 function?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of treatment failure for a CYP2D6 ultrarapid metabolizer taking a standard dose of ondansetron?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"ondansetron\", \"Gene Name\": \"CYP2D6\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 Genotype and Use of Ondansetron and Tropisetron (December 2016).pdf\", \"Content to Search\": \"Quantified risk data for lack of efficacy in CYP2D6 ultrarapid metabolizers using ondansetron\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended dose of liraglutide for a patient with a specific variant in the GLP-1 receptor (GLP1R) gene?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the dosing recommendation for oxcarbazepine in a patient who is a carrier of the HLA-A*31:01 allele?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"oxcarbazepine\", \"Gene Name\": \"HLA-A\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for HLA Genotype and Use of Carbamazepine and Oxcarbazepine: 2017 Update (December 2017).pdf\", \"Content to Search\": \"Clinical dosing recommendation for oxcarbazepine in HLA-A*31:01 positive individuals\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the expected plasma fluvastatin concentrations in an individual with SLCO1B1 intermediate function?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"fluvastatin\", \"Gene Name\": \"SLCO1B1\", \"CPIC Guideline Name\": \"The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf\", \"Content to Search\": \"Plasma concentration ranges or AUC data for fluvastatin in individuals with SLCO1B1 intermediate function.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended pindolol dose for an individual with the ADRB2 Gly16Arg polymorphism?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"pindolol\", \"Gene Name\": \"ADRB2\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Dose adjustment protocol for pindolol based on ADRB2 Gly16Arg genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended dose of regorafenib for a patient with a UGT1A9 promoter polymorphism?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How do CYP3A4 genotypes map to venetoclax clearance and TLS risk phenotypes?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of the CYP2B6 enzyme in the metabolism of vilazodone?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"vilazodone\", \"Gene Name\": \"CYP2B6\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf\", \"Content to Search\": \"Description of CYP2B6's role in vilazodone metabolism.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of sprue-like enteropathy with olmesartan in individuals with specific CES1 variants?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of severe hyperbilirubinemia with simeprevir in individuals with the SLCO1B1 c.521T>C polymorphism?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How should sertraline dosing be adjusted for a CYP2C19 poor metabolizer?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"sertraline\", \"Gene Name\": \"CYP2C19\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf\", \"Content to Search\": \"Dose adjustment protocol for sertraline in CYP2C19 poor metabolizers.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended dose of isoniazid for a patient with the NAT2 rapid acetylator phenotype?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of the SLCO1B1 transporter in the pharmacokinetics of simvastatin?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"simvastatin\", \"Gene Name\": \"SLCO1B1\", \"CPIC Guideline Name\": \"The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf\", \"Content to Search\": \"Description of SLCO1B1's role as a hepatic uptake transporter affecting simvastatin clearance.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the target minimum inhibitory concentration (MIC) for cefuroxime based on the PBP genotype of the infecting organism?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of major bleeding events with edoxaban in patients with specific ABCB1 variants?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended sufentanil dose for an individual with a COMT low-activity genotype?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"sufentanil\", \"Gene Name\": \"COMT\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf\", \"Content to Search\": \"Dose adjustment protocol for sufentanil in individuals with a COMT low-activity genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of hand-foot skin reaction with sorafenib in individuals with low-activity UGT1A9 variants?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "Are there combined CYP2C8 and CYP2C9 genotype considerations for aceclofenac dosing?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"aceclofenac\", \"Gene Name\": \"CYP2C8\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf\", \"Content to Search\": \"Guidance on combined CYP2C8/CYP2C9 genotypes for aceclofenac therapy.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "Which diplotypes define a CYP2C9 intermediate metabolizer?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"piroxicam\", \"Gene Name\": \"CYP2C9\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf\", \"Content to Search\": \"Diplotype definitions for the CYP2C9 intermediate metabolizer phenotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended dosing for amikacin in an individual with a pathogenic MT-RNR1 variant?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"amikacin\", \"Gene Name\": \"MT-RNR1\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for MT-RNR1 and Aminoglycosides (May 2021).pdf\", \"Content to Search\": \"Dosing recommendations or alternative therapies for amikacin in patients with pathogenic MT-RNR1 variants.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended dose of rosiglitazone for a patient identified as a CYP2C8 poor metabolizer?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How do SLC22A2 genotypes correlate with pramipexole elimination phenotypes?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the risk of non-response for an individual with the HTR2A rs6313 G/G genotype taking vilazodone?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"vilazodone\", \"Gene Name\": \"HTR2A\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf\", \"Content to Search\": \"Quantified risk or odds ratio for treatment non-response in vilazodone users with the HTR2A rs6313 G/G genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of the IL-2 receptor alpha chain (IL2RA), and how do its variants alter T-cell response to IL-2 therapy?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended simvastatin dose for a CYP3A5 poor metabolizer (non-expresser)?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"simvastatin\", \"Gene Name\": \"CYP3A5\", \"CPIC Guideline Name\": \"The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf\", \"Content to Search\": \"Dose adjustment protocol for simvastatin in CYP3A5 poor metabolizers.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of the CYP2B6 enzyme in the metabolism of fluoxetine?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"fluoxetine\", \"Gene Name\": \"CYP2B6\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf\", \"Content to Search\": \"Description of CYP2B6's role in the metabolic pathway of fluoxetine.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the role of the CYP2D6 enzyme in the metabolic pathway of clonidine?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the expected pharmacodynamic effects (e.g., change in heart rate or blood pressure) in a patient with the ADRA2C Ins/Del polymorphism taking bisoprolol?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"bisoprolol\", \"Gene Name\": \"ADRA2C\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Pharmacodynamic data (heart rate, blood pressure response) for bisoprolol stratified by ADRA2C genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended propranolol dose for a CYP2D6 poor metabolizer?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"propranolol\", \"Gene Name\": \"CYP2D6\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Dose adjustment protocol for propranolol in CYP2D6 poor metabolizers.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the expected hematological changes in a G6PD deficient individual exposed to sulfasalazine?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"sulfasalazine\", \"Gene Name\": \"G6PD\", \"CPIC Guideline Name\": \"Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf\", \"Content to Search\": \"Data on hematological parameters in G6PD deficient individuals after sulfasalazine administration.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What diplotypes define a CYP2D6 poor metabolizer?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"vilazodone\", \"Gene Name\": \"CYP2D6\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf\", \"Content to Search\": \"Diplotype definitions and activity scores for the CYP2D6 poor metabolizer phenotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the risk of treatment failure with citalopram in patients with high-activity ABCB1 variants?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of P-glycoprotein (ABCB1) in the renal excretion of digoxin?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "Is the dose of peginterferon alfa-2b adjusted based on a patient's IFNL3 genotype?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"peginterferon alfa-2b\", \"Gene Name\": \"IFNL3\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for IFNL3 (IL28B) Genotype and PEG interferon-alpha-based Regimens (February 2014).pdf\", \"Content to Search\": \"Dosing recommendations for peginterferon alfa-2b based on IFNL3 genotype\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of subtherapeutic theophylline levels in individuals with high CYP2E1 activity?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the dosing recommendation for hydromorphone in pediatric patients with a COMT low-activity genotype?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"hydromorphone\", \"Gene Name\": \"COMT\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf\", \"Content to Search\": \"Pediatric dosing guidelines for hydromorphone adjusted for COMT low-activity genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of hypertension and proteinuria with bevacizumab in individuals with specific VEGF-A variants?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended dose of dasatinib for a patient who is a CYP3A4 poor metabolizer?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How do ABCB1 genotypes correlate with oxycodone analgesic response phenotypes?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of adverse effects for a CYP2D6 ultrarapid metabolizer taking morphine?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"morphine\", \"Gene Name\": \"CYP2D6\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf\", \"Content to Search\": \"Quantified risk data for adverse effects in CYP2D6 ultrarapid metabolizers using morphine.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of the CYP2D6 enzyme in the metabolism of carvedilol?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"carvedilol\", \"Gene Name\": \"CYP2D6\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Description of CYP2D6's role in carvedilol metabolism.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "Which genotypes for the IFNL3 SNP rs12979860 define a favorable response phenotype to peginterferon alfa-2a therapy?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"peginterferon alfa-2a\", \"Gene Name\": \"IFNL3\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for IFNL3 (IL28B) Genotype and PEG interferon-alpha-based Regimens (February 2014).pdf\", \"Content to Search\": \"Genotype definitions for the IFNL3 favorable response phenotype\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended starting dose of levothyroxine for a patient with the DIO2 Thr92Ala polymorphism?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended pindolol dose for a CYP2D6 poor metabolizer?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"pindolol\", \"Gene Name\": \"CYP2D6\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Dose adjustment protocol for pindolol in CYP2D6 poor metabolizers.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the mechanism by which chlorpropamide causes oxidative stress leading to hemolysis in G6PD deficient individuals?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"chlorpropamide\", \"Gene Name\": \"G6PD\", \"CPIC Guideline Name\": \"Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf\", \"Content to Search\": \"Biochemical mechanism of chlorpropamide-induced oxidative damage to red blood cells in the context of G6PD deficiency.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of the SLCO1B1 transporter in the pharmacokinetics of fluvastatin?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"fluvastatin\", \"Gene Name\": \"SLCO1B1\", \"CPIC Guideline Name\": \"The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf\", \"Content to Search\": \"Description of SLCO1B1's role as a hepatic uptake transporter affecting fluvastatin clearance.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of SAMS for a CYP3A5 normal metabolizer (expresser) taking pitavastatin?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"pitavastatin\", \"Gene Name\": \"CYP3A5\", \"CPIC Guideline Name\": \"The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf\", \"Content to Search\": \"Quantified risk data for SAMS in CYP3A5 normal metabolizers using pitavastatin.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What diplotypes define a CYP2B6 poor metabolizer?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"escitalopram\", \"Gene Name\": \"CYP2B6\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf\", \"Content to Search\": \"Diplotype definitions and activity scores for the CYP2B6 poor metabolizer phenotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of SAMS for a CYP3A4 poor metabolizer taking fluvastatin?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"fluvastatin\", \"Gene Name\": \"CYP3A4\", \"CPIC Guideline Name\": \"The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf\", \"Content to Search\": \"Quantified risk data for SAMS in CYP3A4 poor metabolizers using fluvastatin.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the dosing recommendation for carvedilol in pediatric patients with the ADRB1 Arg389Gly polymorphism?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"carvedilol\", \"Gene Name\": \"ADRB1\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Pediatric dosing guidelines for carvedilol adjusted for ADRB1 genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended sotalol dose for a CYP2D6 poor metabolizer?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"sotalol\", \"Gene Name\": \"CYP2D6\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Dose adjustment protocol for sotalol in CYP2D6 poor metabolizers.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the dosing recommendation for atorvastatin in pediatric patients with ABCG2 decreased function?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"atorvastatin\", \"Gene Name\": \"ABCG2\", \"CPIC Guideline Name\": \"The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf\", \"Content to Search\": \"Pediatric dosing guidelines for atorvastatin adjusted for ABCG2 decreased function.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How do ABCB1 genotypes correlate with edoxaban peak concentration phenotypes?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "Are there specific ribavirin dosing guidelines for pediatric patients based on their IFNL3 genotype?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"ribavirin\", \"Gene Name\": \"IFNL3\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for IFNL3 (IL28B) Genotype and PEG interferon-alpha-based Regimens (February 2014).pdf\", \"Content to Search\": \"Pediatric dosing recommendations for ribavirin stratified by IFNL3 genotype\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the risk of reduced efficacy of aprepitant in patients with high CYP3A4 activity?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What G6PD genotypes are classified as deficient (e.g., Class I, II, or III variants)?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"chlorpropamide\", \"Gene Name\": \"G6PD\", \"CPIC Guideline Name\": \"Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf\", \"Content to Search\": \"Definitions of G6PD genotypes and their classification into different functional/phenotypic classes of deficiency.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of hepatotoxicity with lapatinib in individuals with reduced CYP3A4 function?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "Is a dose adjustment for diclofenac recommended based on CYP2C8 genotype?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"diclofenac\", \"Gene Name\": \"CYP2C8\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf\", \"Content to Search\": \"Dose adjustment protocol for diclofenac based on CYP2C8 genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the suggested plasma concentration ranges for propranolol in a TPMT intermediate metabolizer?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the expected plasma bisoprolol concentrations in a CYP2D6 ultrarapid metabolizer?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"bisoprolol\", \"Gene Name\": \"CYP2D6\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Plasma concentration ranges or AUC data for bisoprolol in CYP2D6 ultrarapid metabolizers.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the quantified risk of acute hemolytic anemia for a G6PD deficient individual taking tafenoquine?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"tafenoquine\", \"Gene Name\": \"G6PD\", \"CPIC Guideline Name\": \"Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf\", \"Content to Search\": \"Incidence rates or risk multipliers for acute hemolytic anemia with tafenoquine use in G6PD deficient patients.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What GRK5 polymorphisms are associated with altered beta-blocker response?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"labetalol\", \"Gene Name\": \"GRK5\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Definitions of GRK5 variants (e.g., Gln41Leu) and their association with beta-blocker efficacy.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of the CYP3A4 enzyme in the metabolism of spironolactone?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended nadolol dose for an individual with the ADRB2 Gly16Arg polymorphism?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"nadolol\", \"Gene Name\": \"ADRB2\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Dose adjustment protocol for nadolol based on ADRB2 Gly16Arg genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended hydrocodone dose for an individual with a COMT low-activity genotype?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"hydrocodone\", \"Gene Name\": \"COMT\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf\", \"Content to Search\": \"Dose adjustment protocol for hydrocodone in individuals with a COMT low-activity genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the suggested therapeutic range for plasma methadone concentrations in a patient with an OPRM1 variant leading to increased receptor expression?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"methadone\", \"Gene Name\": \"OPRM1\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf\", \"Content to Search\": \"Therapeutic drug monitoring values for methadone stratified by OPRM1 genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What SLC6A4 variants (e.g., 5-HTTLPR) are associated with altered fluvoxamine response?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"fluvoxamine\", \"Gene Name\": \"SLC6A4\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf\", \"Content to Search\": \"List and description of SLC6A4 variants and their corresponding impact on fluvoxamine response.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of the OATP1B1 transporter (encoded by SLCO1B1) in the hepatic uptake of caspofungin?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the expected pharmacodynamic effects on cardiac function in a patient with the GRK5 Gln41Gln genotype taking pindolol?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"pindolol\", \"Gene Name\": \"GRK5\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Pharmacodynamic data for pindolol stratified by GRK5 genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "Are there combined CYP2C8 and CYP2C9 genotype considerations for naproxen dosing?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"naproxen\", \"Gene Name\": \"CYP2C8\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf\", \"Content to Search\": \"Guidance on combined CYP2C8/CYP2C9 genotypes for naproxen therapy.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of hepatotoxicity for a CYP2C9 poor metabolizer taking lumiracoxib?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"lumiracoxib\", \"Gene Name\": \"CYP2C9\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf\", \"Content to Search\": \"Quantified risk data for hepatotoxicity in CYP2C9 poor metabolizers using lumiracoxib.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the dosing recommendation for labetalol in pediatric patients with the ADRB1 Arg389Gly polymorphism?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"labetalol\", \"Gene Name\": \"ADRB1\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Pediatric dosing guidelines for labetalol adjusted for ADRB1 genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What G6PD genotypes are classified as deficient (e.g., Class I, II, or III variants)?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"probenecid\", \"Gene Name\": \"G6PD\", \"CPIC Guideline Name\": \"Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf\", \"Content to Search\": \"Definitions of G6PD genotypes and their classification into different functional/phenotypic classes of deficiency.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of the CYP2C9 enzyme in the metabolic activation of tamoxifen?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of constipation with verapamil in individuals with reduced CYP3A4 function?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of the OPRM1 gene product in the context of hydromorphone therapy?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"hydromorphone\", \"Gene Name\": \"OPRM1\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf\", \"Content to Search\": \"Explanation of OPRM1's role as the mu-opioid receptor, the primary target for hydromorphone.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the known functional classifications of CYP2C8 alleles relevant to NSAID metabolism?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"indomethacin\", \"Gene Name\": \"CYP2C8\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf\", \"Content to Search\": \"Allele function table or definitions for CYP2C8.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of the SLC6A4 gene product in the mechanism of action of vortioxetine?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"vortioxetine\", \"Gene Name\": \"SLC6A4\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf\", \"Content to Search\": \"Description of the serotonin transporter's (SERT) role as a primary target of vortioxetine.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of major adverse cardiovascular events (MACE) for a CYP2C19 poor metabolizer taking clopidogrel?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"clopidogrel\", \"Gene Name\": \"CYP2C19\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2C19 Genotype and Clopidogrel Therapy: 2022 update (January 2022).pdf\", \"Content to Search\": \"Risk multipliers or incidence rates for MACE in CYP2C19 poor metabolizers on clopidogrel.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the target plasma concentrations for lumefantrine in a patient with a CYP3A4 poor metabolizer genotype?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the mechanism by which sulfadiazine causes oxidative stress leading to hemolysis in G6PD deficient individuals?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"sulfadiazine\", \"Gene Name\": \"G6PD\", \"CPIC Guideline Name\": \"Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf\", \"Content to Search\": \"Biochemical mechanism of sulfadiazine-induced oxidative damage to red blood cells in the context of G6PD deficiency.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of the ADRB2 gene product in the context of sotalol therapy?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"sotalol\", \"Gene Name\": \"ADRB2\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Explanation of ADRB2's role as the beta-2 adrenergic receptor and its relevance to sotalol therapy.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How should vincristine dosing be adjusted for a patient who is a CYP3A5 expresser?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended dose of linezolid for a patient with a specific MAOA uVNTR polymorphism?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the risk of poor response to desvenlafaxine for individuals with the HTR2A rs7997012 A allele?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"desvenlafaxine\", \"Gene Name\": \"HTR2A\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf\", \"Content to Search\": \"Quantified risk or clinical evidence for altered desvenlafaxine efficacy in patients with the HTR2A rs7997012 A allele.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What diplotypes define a CYP2D6 poor metabolizer?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"citalopram\", \"Gene Name\": \"CYP2D6\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf\", \"Content to Search\": \"Diplotype definitions and activity scores for the CYP2D6 poor metabolizer phenotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of the SLC6A4 gene product in the mechanism of action of paroxetine?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"paroxetine\", \"Gene Name\": \"SLC6A4\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf\", \"Content to Search\": \"Description of the serotonin transporter's (SERT) role as the primary target of paroxetine.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "Is phenazopyridine contraindicated or should dosing be adjusted for a G6PD deficient individual?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"phenazopyridine\", \"Gene Name\": \"G6PD\", \"CPIC Guideline Name\": \"Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf\", \"Content to Search\": \"Dosing protocol or contraindication for phenazopyridine in G6PD deficient individuals.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the suggested therapeutic response metric for IL-2 in renal cell carcinoma based on a patient's IL2RA genotype?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the dosing recommendation for ticagrelor in patients with known CYP3A4 variants who are also on a strong CYP3A4 inhibitor?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended escitalopram dose for a CYP2D6 poor metabolizer?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"escitalopram\", \"Gene Name\": \"CYP2D6\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf\", \"Content to Search\": \"Dose adjustment protocol for escitalopram in CYP2D6 poor metabolizers.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of hyperbilirubinemia with pazopanib in individuals with reduced UGT1A1 function (Gilbert's syndrome)?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What genotypes of the HTR2A gene (e.g., rs6313) are associated with altered vortioxetine response?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"vortioxetine\", \"Gene Name\": \"HTR2A\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf\", \"Content to Search\": \"Definitions of HTR2A genotypes and their association with vortioxetine efficacy.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How do CYP2B6 genotypes correlate with selegiline clearance phenotypes?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended hydrocodone dose for a CYP2D6 ultrarapid metabolizer?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"hydrocodone\", \"Gene Name\": \"CYP2D6\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf\", \"Content to Search\": \"Specific dosing recommendation or contraindication for hydrocodone in CYP2D6 ultrarapid metabolizers.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of clozapine toxicity when a patient with low CYP1A2 activity consumes large amounts of caffeine?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended dose of dalfampridine for a patient with a low-function SLC22A2 (OCT2) genotype?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How do CYP3A4 genotypes map to capmatinib clearance phenotypes?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the quantified risk of liver injury for leflunomide users with CYP2C9*3 alleles?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of the ABCG2 transporter in the excretion of febuxostat?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How does the CYP2C8*3 allele affect the pharmacokinetics of naproxen?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"naproxen\", \"Gene Name\": \"CYP2C8\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf\", \"Content to Search\": \"Pharmacokinetic data on naproxen exposure related to the CYP2C8*3 allele.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How do SRD5A2 genotypes correlate with finasteride efficacy phenotypes for androgenetic alopecia?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of the SLCO1B1 transporter in the pharmacokinetics of atorvastatin?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"atorvastatin\", \"Gene Name\": \"SLCO1B1\", \"CPIC Guideline Name\": \"The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf\", \"Content to Search\": \"Description of SLCO1B1's role as a hepatic uptake transporter affecting atorvastatin clearance.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the quantified risk of acute hemolytic anemia for a G6PD deficient individual taking sulfisoxazole?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"sulfisoxazole\", \"Gene Name\": \"G6PD\", \"CPIC Guideline Name\": \"Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf\", \"Content to Search\": \"Incidence rates or risk multipliers for acute hemolytic anemia with sulfisoxazole use in G6PD deficient patients.\"}]"}]}
